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Rett Syndrome (RTT) is a neurodevelopmental disease affecting mainly females. 
Neurological diseases are traditionally hard to model in a human context due to 
inaccessibility of relevant cell types, but induced pluripotent stem cells (iPSCs) 
offers a viable route of access to neural cells from a human patient. In this thesis, I 
describe the modelling of RTT using iPSCs reprogrammed from RTT patients 
carrying mutations in the Methyl CpG binding Protein 2 (MeCP2) gene. 
First, I derived isogenic wildtype (WT) and mutant (MT) iPSCs from RTT 
patients. With these isogenic iPSCs, I induced neural precursor cells (NPCs) and 
found that MT NPCs showed reduced migration compared to WT NPCs, 
indicating the possible involvement of NPCs in the disease. I also generated 
astrocytes from isogenic iPSCs and found abnormalities in the proliferation rate 
and cytokine secretions of MT astrocytes. Finally, I showed that microglia 
derived from MT iPSCs have reduced mobility and phagocytosis compared to 
WT microglia. As MeCP2 is a transcriptional regulator, gene expression analysis 
was carried out in the different cell types (i.e. NPCs, astrocytes and microglia) to 
determine possible target genes of MeCP2 in each cell type. This work provides 
evidence of NPCs and glia involvement in RTT and represents a promising tool 
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Chapter 1: Introduction 
1.1 Rett Syndrome  
1.1.1 Introduction to Rett Syndrome 
Rett Syndrome (RTT) is a neurological disorder that occurs almost exclusively 
in females with an incidence of 1 in 10 000 female live births (Chahrour and 
Zoghbi, 2007). It is one of the most common genetic causes of severe mental 
retardation in females. Patients with RTT have a seemingly normal post-natal 
developmental period after which symptoms start to appear in early childhood. 
These include cognitive impairment, loss of motor, language and social skills, 
microcephaly and stereotypic hand movements. It was this distinctive hand 
movement that led to an Austrian pediatrician, Dr Andreas Rett to first 
document this disorder in 1966. He had observed female patients with similar 
hand movements and clinical features in his clinic in Vienna and subsequently 
extended his observations to other parts of Europe.  However, it was not until 
1983, when a Swedish neurologist, Dr Bengt Hagberg published an article on 
RTT, that RTT gained widespread recognition in the medical community. The 
disease was termed “Rett Syndrome” to recognize and honour the work of Dr 
Andreas Rett. 
1.1.2 Stages of the disease and clinical manifestations 
The RTT infant from birth first appears healthy, has normal growth, and is 
able to achieve early developmental milestones. The course of the disease and 
severity of symptoms vary from patient to patient but in general, RTT can be 
divided into 4 stages. They are: 


Early onset (6-18 months): Symptoms are usually subtle and the child has less 
eye contact and exhibits deceleration of head growth. Atypical socio-
communicative function and speech-language development have also been 
detected in this early stage (Bartl-Pokorny et al., 2013; Marschik et al., 2013).  
Rapid Regression (1-4 years): The patient loses purposeful hand skills and 
develops stereotypical hand movement such as wringing, washing, clapping or 
putting the hand to the mouth. General motor functions including walking are 
also affected (apraxia). The patient now fails to acquire new language skills 
and may lose previously acquired language skills. Mental retardation and 
autistic features become apparent now. The patient also has general growth 
retardation and weight loss (by age 2, most RTT patients are below the 5th 
percentile of the normal female population) (Percy and Lane, 2005). 
Plateau (2-10 years): There is no further significance deterioration and there 
may be improvement in communication and social skills but most symptoms 
remain. Many patients remain in this stage for the majority of their lives.  
Late Motor Deterioration (10 years onwards): The patient suffers gradual 
loss of mobility and appearance of parkinsonian features such as shaking and 
rigidity of movements (FitzGerald et al., 1990).  
Some other features of RTT are microcephaly, breath holding, 
hyperventilation, seizures, teeth grinding (bruxism), curvature of the spine 
(scoliosis) and cold hands and feet (Chahrour and Zoghbi, 2007; Han et al., 
2012; Percy and Lane, 2004). Life expectancy of RTT patients is not well 
studied but patients surviving into the early thirties have been recorded 


(Halbach et al., 2013). There is currently no cure for RTT and most patients 
require full time care in all aspects of life.  
1.1.3 Brain pathology of RTT patients 
From post-mortem studies, brain weight of RTT patients was decreased by 12-
34%, but not other major organs such as heart, liver, lungs and kidney based 
on height (Armstrong et al., 1999; Jellinger et al., 1988). Besides a decrease in 
brain weight, other neuropathological defects observed are reduced neuronal 
soma size, increased cell packing density (Bauman et al., 1995a, b), reduced 
dendritic arborisation and reduced dendritic spine numbers especially in the 
frontal, motor and temporal lobes (Armstrong et al., 1995; Belichenko et al., 
1994; Chapleau et al., 2009; Kaufmann and Moser, 2000; Schule et al., 2008). 
It is generally accepted that there is no obvious neurodegeneration in the RTT 
brain (Armstrong, 2005). 
1.1.4 RTT is caused by mutations in the MeCP2 gene 
As 99% of RTT cases are sporadic, it was difficult to identify the gene/genes 
responsible for the disorder. However, as RTT occurs mainly in females, it 
was likely that the gene/genes responsible are X-linked. Using this clue, 
exclusion mapping of rare familial cases of RTT led to the identification of 
chromosome region Xq28 to contain the “RTT gene” (Ellison et al., 1992; 
Sirianni et al., 1998). In 1999, systemic gene screening of this region of RTT 
patients led to the identification of Methyl CpG binding protein 2 (MeCP2) as 
the causative gene in the majority of RTT cases (Amir et al., 1999).  
RTT is primarily caused by mutation in MeCP2, but mutations in cyclin-
dependent kinase-like 5 (CDKL5) and Forkhead box G1 (FOXG1) can lead to 


neurological symptoms that resemble RTT (Allou et al., 2012; Fehr et al., 
2013; Kortum et al., 2011; Maortua et al., 2012). CDKL5 is located on the X-
chromosome and encodes for a serine/threonine kinase protein. One of its 
targets is MeCP2 though its other targets remain unknown (Bertani et al., 2006; 
Mari et al., 2005). FOXG1 is located on 14q12 and encodes for a 
transcriptional repressor that is important in brain development. 
1.1.5 MeCP2 gene location and transcript variants 
The MeCP2 gene is located at chromosome Xq28. It is flanked by the 
interleukin-1 receptor (IRAK1) and a long-wavelength sensitive opsin 
(OPN1LW) gene which is transcribed in the opposite strand (Singh et al., 
2008). MeCP2 has four exons (exon 1-4) and is alternatively spliced to give 
two different protein isoforms, MeCP2_e1 and MeCP2_e2 (Kriaucionis and 
Bird, 2004; Mnatzakanian et al., 2004; Reichwald et al., 2000)(Fig.1.1). 
MeCP2_e1 is 498 amino acid long and is encoded by exons 1,3 and 4 while 
MeCP2_e2 is 486 amino acid long and encoded by exons 2, 3 and 4 
(Kriaucionis and Bird, 2004; Mnatzakanian et al., 2004). In both mouse and 
human, MeCP2_e1 is the predominant isoform expressed in the post-natal 
brain (Dragich et al., 2007; Kriaucionis and Bird, 2004; Mnatzakanian et al., 
2004; Yasui et al., 2014). It was also reported that Mecp2_e2 has a later onset 
of expression than Mecp2_e1 (Olson et al., 2014). Mecp2_e1 showed uniform 
expression across the brain while Mecp2_e2 has a more regional specific 
expression with a higher expression in olfactory bulb and cerebellum (Olson et 
al., 2014).  Mecp2_e1 is more efficiently translated than Mecp2_e2 
(Kriaucionis and Bird, 2004), and has greater stability in neurons (Yasui et al., 


2014). Loss of the Mecp2_e1, but not Mecp2_e2 can lead to RTT symptoms 
in mice (Itoh et al., 2012; Yasui et al., 2014). In contrast, expression of either 
isoforms can lead to rescue of symptoms in RTT mouse model though 
Mecp2_e1 has a better efficiency (Giacometti et al., 2007; Kerr et al., 2012; 
Luikenhuis et al., 2004). Mecp2_e2 is however found to be crucial in placenta 
development and embryo survival (Itoh et al., 2012). In addition, Mecp2_e2 is 
found to be upregulated in dying neurons and overexpression of the Mecp2_2 
can promote neuronal death and this can be inhibited by FoxG1 (Dastidar et al., 
2012). Each isoform has its’ distinct roles, but there is also partial overlapping 
functions (i.e Mecp2_e2 can effect a rescue). So far, no MeCP2-e2 specific 
mutation has been reported in RTT. 
 
Fig 1.1 Schematic representations of MeCP2 transcript variants and 
respective protein isoforms. MeCP2 has 2 transcripts variants. Transcript 
variant 1, composed of exons 2, 3 and 4 is translated to give protein isoform 
MeCP2-e2 (486 aa). Transcript variant 2 is composed of exons 1, 3 and 4 and 
is translated to give protein isoform MeCP2-e1 (498 aa). 
1.1.6 MeCP2 protein structure and functions 
The MeCP2 protein was first discovered by Adrian Bird in 1992 as a 53KDa 
nuclear protein that could bind to methylated CpGs (Lewis et al., 1992). It 


belongs to a family of DNA-binding proteins with the Methyl-CpG Binding 
Domain (MBD) sequence motif. In mammals, the 4 other members of the 
family are MBD1-4 and all members of the family are expressed ubiquitously 
(Hendrich and Tweedie, 2003). Incidentally, there is a MeCP1 but it is a 
complex consisting of multiple proteins rather than a single polypeptide and 
hence not part of the family (Cross et al., 1997; Feng and Zhang, 2001). 
Structural analyses of MeCP2 based on trypsin digestion experiments indicate 
that it contains 6 biochemically distinct domains (Adams et al., 2007)(Fig 1.2). 
They are the N-terminal domain, the MBD, the inter-domain, the 
Transcriptional Repression Domain (TRD) and the C-terminal domain α and β 
(Adams et al., 2007). The 2 most well characterized domains are the MBD and 
the TRD. The MBD is described as the region that is sufficient to recognize 
and bind to methylated DNA although it can also bind to non-methylated 
DNA with a lower affinity (~3 fold lower)(Fraga et al., 2003; Nan et al., 1993). 
The MBD has been found to be able to bind to higher ordered DNA structures 
like un-methylated four-way DNA junction and heterochromatin (Galvao and 
Thomas, 2005; Nan et al., 1996) More recently, the MBD has also been shown 
to be able to bind specifically to 5-hydroxymethylcytosine, an oxidized form 
of 5-methylcytosine (Hashimoto et al., 2012; Mellen et al., 2012). The TRD is 
a segment found to be able to repress transcription through recruitment and 
interaction of a repressor complex involving histone deacetylase (HDAC) and 
the corepressor SIN3A (Jones et al., 1998; Nan et al., 1998). The TRD was 
also found to be able to bind to the NCoR/SMRT corepressors (Lyst et al., 
2013). Besides transcriptional repression, the TRD (aa 195-329) has also been 
found to be able to bind to the YB1 protein which is involved in alternative 


splicing (Young et al., 2005). The TRD also contains an AT-hook (regions of 
a protein that bind to AT-rich DNA) that is necessary for DNA binding and 
compaction of chromatin (Baker et al., 2013). The C-terminal domain is 
largely uncharacterized, but it is thought to promote the binding of MeCP2 to 
DNA and contains a WW domain that is predicted to mediate interactions with 
proteins (Buschdorf and Stratling, 2004; Chandler et al., 1999). While the 
functions of the other domains beside MBD and TRD are not established, 
mutations resulting in RTT have been found throughout the MeCP2 gene 
indicating that every domain have important functions. 
 
Fig 1.2 Schematic representation of the MeCP2 protein. MeCP2 can be 
divided into 6 domains, the HMGD1, MBD, HMGD2, TRD, CTD-α and 
CTD-β. Arrows depict relative position of the 8 most common mutations in 
RTT and they all are results of C>T substitutions (adapted from (Gonzales et 
al., 2012)). 
 
1.1.7 MeCP2 Mutations 
Single C >T substitutions at one of a number of sites are the most common 
mutations reported (RettBASE: IRSF MECP2 Variation Database) (Fig. 1.2). 
RTT patients with multiple mutations in the MeCP2 gene have been reported 
though multiple mutations are not reported to increase the severity of the 
symptoms (Chapleau et al., 2013). It is worth noting that not all individuals 
with a mutation in MeCP2 will have a RTT phenotype, possibly due to non-
	

deleterious effect, X-inactivation status and/or modifier genes (Hoffbuhr et al., 
2001; Takahashi et al., 2008). Interestingly, studies investigating the parental 
origin of MeCP2 mutations in sporadic cases of RTT found that most de novo 
mutations of MeCP2 occur on the paternally derived X-chromosome (71-96%) 
(Girard et al., 2001; Trappe et al., 2001; Zhang et al., 2012).  
1.1.8 MeCP2 mutations in males 
Mutations in MeCP2 in males usually results in 3 outcomes: prenatal or early 
infant mortality, males with neurological symptoms not classified as RTT and 
males with classic RTT. 
Males surviving with MeCP2 mutations but not classified as RTT cases have 
symptoms that range from severe neonatal encephalopathy to mild mental 
retardation (Moog et al., 2003; Villard, 2007). In familial cases of RTT, males 
who have identical MeCP2 mutation as their RTT sister have severe 
encephalopathy and often die in the early years (Hoffbuhr et al., 2001; Villard 
et al., 2000). 
In males with classic RTT, 2 unique genetic conditions can lead to male 
patients having a mixture of WT and MT cells akin to the female patient. 
Klinefelter Syndrome is a condition in which there is an extra copy of X 
chromosome (47, XXY). Random X-inactivation occurs such that only one 
copy of X chromosome is expressed in any one cell. If one of the X-
chromosome carries a mutation in the MeCP2 gene, the male subject can 
suffer from RTT.  In another condition that can lead to RTT in males, diploid 




MeCP2 gene in other cells (Armstrong et al., 2001; Topcu et al., 2002). This is 
known as somatic mosaicism and is thought to occur early in development 
when a cell undergoes mutation in the MeCP2 gene thus leading to subsequent 
daughter cells carrying the mutation. A small number of males with mutation 
in MeCP2 but seemingly without Klinefelter or somatic mosaicism have also 
been reported to have symptoms similar to RTT (Dayer et al., 2007; 
Masuyama et al., 2005).  
1.1.9 Duplication of MeCP2 
MeCP2 duplication syndrome is a condition in which the patient has early 
infantile hypotonia, spasticity, developmental delays, mental retardation, 
dysmorphic features (brachycephaly, large ears and flat nasal bridge), autistic 
features, seizures and recurrent infection of the respiratory tract (del Gaudio et 
al., 2006; Friez et al., 2006; Van Esch et al., 2005). The cause of this condition 
is typically a duplication of the Xq28 region due to abnormal chromosomal 
duplication. In all cases reported, the duplicated region always contains the 
MeCP2 gene, resulting in a gain of MeCP2 dosage (Ramocki et al., 2010). The 
majority of MeCP2 duplication syndrome cases identified are males who 
inherited the abnormal X-chromosome from their asymptomatic carrier mother. 
Females with MeCP2 gene duplication are typically asymptomatic or have 
mild symptoms due to X-chromosome inactivation skewing towards the 
abnormal X chromosome (Ramocki et al., 2010; Van Esch, 2012). The effects 
of increased MeCP2 dosage show that there need to be a balance of MeCP2 in 




1.1.10 Knockout mouse models of RTT 
The earliest attempts to create a Mecp2-null mouse model from embryonic 
stem cells (ESC) failed due to embryonic lethality and suggested that Mecp2 is 
essential for embryonic development. (Tate et al., 1996) This was disproven 
when two groups successfully generated Mecp2-null mouse models using Cre-
Lox technology (Chen et al., 2001; Guy et al., 2001). Mice were first 
generated from ESC in which part of the Mecp2 gene was flanked by lox-P 
sites (Mecp2lox).  These Mecp2lox mice were then crossed with deleter mice in 
which Cre is expressed. Offsprings carrying both the Cre transgene and 
Mecp2lox would thus have part of the Mecp2 gene deleted resulting in 
inactivation of the Mecp2 gene. The Mecp2-null mouse generated by the Bird 
lab has deletion of exon 3 and 4 while the one generated by the Jaenish Lab 
contains a deletion of exon 3. In both models, null offsprings (Mecp2-/y) were 
viable and healthy during the first few weeks of life. Between 3-8 weeks, 
symptoms such as uncoordinated gait, trembling, reduced movement, 
respiratory problems, weight loss and hindlimb clasping start to show and 
these Mecp2-null mice died at 10-16 weeks. Brains of Mecp2-null mice were 
smaller than wildtypes with an increase in cell packing density and reduction 
in neuronal size (Chen et al., 2001). Mecp2 heterozygous females mice 
(Mecp2+/-) were born healthy and only a small percentage start to show any 
symptoms until a much later age of 3-4 months (Chen et al., 2001; Guy et al., 
2001). Symptoms observed were weight gain, reduced activity and ataxic gait 
similar to those of Mecp2-null male mice but were generally milder, i.e they 
did not rapidly deteriorate and could live beyond a year and some did not 
show symptoms at all (Guy et al., 2001).  For this reason, most mouse studies 
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of RTT are done using male mice although there have been an interest in the 
use of the female mouse model in recent years (Garg et al., 2013; Lang et al., 
2014; Schaevitz et al., 2013). 
1.1.11 Mutant mouse models of RTT 
In addition to Mecp2-null mice models, mouse models with different Mecp2 
mutations have been generated. Here I will describe some of the mouse 
models.  
T158A. This mutation reduces the binding of Mecp2 to methylated DNA and 
decreases Mecp2 stability (Goffin et al., 2012). Mice with this mutation had 
normal development in the first 4 weeks followed by hindlimb clasping, 
reduced weight from week 4, followed by weight gain to WT levels and 
seizures. Mutant mice also had reduced brain size, reduced locomotion, 
impaired motor functions, learning and memory deficits and a shortened 
lifespan of < 16 weeks (Goffin et al., 2012). 
R168X. This mutation causes a premature truncation leaving only the MBD. 
Mice with this mutation showed hypoactivity, forelimb stereotypies, breathing 
irregularities, weight changes, hind limb atrophy, tremors, scoliosis and 
reduced lifespan of 12-14 weeks (Lawson-Yuen et al., 2007). Other 
phenotypes reported in these mice include decreased anxiety and impaired nest 
building (Wegener et al., 2014). 
R270X. This mutation affects the binding of Mecp2 to chromatin, resulting in 
a failure of Mecp2 to maintain chromatin structure (Baker et al., 2013). Mice 
with this mutation develope normally till 4-6 weeks when symptoms start to 
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show. These symptoms include weight gain at week 7, tremor, gait 
abnormalities, motor dysfunction, smaller brain size, and a reduced lifespan of 
around 12 weeks (Baker et al., 2013). 
R306C. This mutation abolishes the interaction between the TRD and the 
NCoR/SMRT (Lyst et al., 2013). These mice are normal for the first 6 weeks 
followed by symptoms such as hindlimb clasping, reduced locomotion, 
impaired motor functions, tremors and with a shortened lifespan of <20 weeks 
(Lyst et al., 2013). 
Premature stop after codon 308. A stop codon was inserted after codon 308 
leaving behind intact MBD and TRD but a truncated C-terminal in this mouse 
model (Shahbazian et al., 2002a). Mice with this mutation have normal 
development for the first 6 weeks, followed by progressive neurological 
symptoms such as tremors, motor impairments, hypoactivity, increased 
anxiety-related behavior, seizures, kyphosis and stereotypic forelimb motions. 
These mice had normal body and brain weight and were able to survive at 
least a year (Shahbazian et al., 2002a).  
In general, these mouse models recapitulate the human RTT phenotype. For 
example, a post-natal and progressive onset of symptoms, motor dysfunctions, 
gait abnormality and cognitive deficits are similar symptoms of RTT patients. 
Forelimb stereotypies and hindlimb clasping seen in mouse models also 
mirrors the human RTT phenotype of hand stereotypies. Mecp2-null mice 
show early onset of symptoms (3-8 weeks), have severe phenotypes and have 
shortened lifespan (10-16 weeks). Mice with mutations affecting the MBD and 
TRD typically show onset of symptoms at (4-6 weeks), severe phenotypes and 
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lifespan of 12-20 weeks while C-terminal truncation mouse model show a 
later onset of symptoms after 6 weeks and can live up to a year. The type of 
mutations in mouse models also reflects the severity of RTT patients as 
patients with C-terminal truncations typically have a milder phenotype than 
those with mutations in the MBD and TRD (Bebbington et al., 2010). 
Several other Mecp2 mouse models have been generated and they include a 
transgenic mouse in which human MeCP2 is overexpressed by ~ 2 fold 
(Collins et al., 2004), inactivation of Mecp2 in specific cell types such as in 
neural lineages, GABAergic neurons and aminergic neurons (Chao et al., 2010; 
Chen et al., 2001; Samaco et al., 2009) or in specific brain regions such as in 
the hypothalamus and basolateral amygdala (Adachi et al., 2009; Fyffe et al., 
2008). Most of these different animal models are reviewed in (Calfa et al., 
2011). Later chapters will describe in details inactivation of mouse models of 
Mecp2 inactivation in astrocyte and microglia. 
1.1.12 Rescue of mouse RTT models 
In 2007, it was shown that re-expression of Mecp2 in symptomatic Mecp2-null 
mice led to phenotypic reversal (Guy et al., 2007). Knock-out mice were first 
made by silencing of Mecp2 through insertion of lox-stop cassette in the 
endogenous Mecp2 gene. These mice developed symptoms similar to Mecp2-
null mice. Removal of the lox-stop cassette resulted in reactivation of 
endogenous Mecp2 and in mice already showing severe symptoms, 
reactivation of Mecp2 showed pronounced reversal of phenotype and 
enhanced lifespan. Importantly, this showed that absence of Mecp2 did not 
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cause irreversible damage, in mice at least, and raised hope that human 
patients could one day have effective treatment. 
Another rescue study was carried out by conditional re-activation of Mecp2 in 
only the brain of Mecp2-null mice (Giacometti et al., 2007). This was 
performed through the use of specific promoters regulating the expression of 
Cre, which in turn facilitates the expression of Mecp2 in an exogeneous lox-
stop cassette. In summary, the use of Nestin Cre (targets all neural cell) and 
Tau Cre (targets post-mitotic neurons) increased the lifespan of null mice from 
10-12 weeks to > 8 months while C93 Cre and C159 Cre (both targeting 
mature neurons) increased lifespan by only 4 weeks. All rescued mice showed 
significantly increased nocturnal activity compared to Mecp2-null mice. These 
findings showed that restoration of Mecp2 in the brain was enough to mediate 
a partial rescue. 
To test the concept of gene therapy, the self-complementary adeno-associated 
virus, scAAV9, was used to deliver Mecp2 cDNA into the Mecp2-null mice 
(Gadalla et al., 2013). Neonatal mice injected with the scAAV9/Mecp2 virus 
showed slightly improved lifespan to 16 weeks and improved motor functions 
compared with control injected mice. In another study, scAAV9 was also used 
to deliver Mecp2 cDNA with increased lifespan of >40weeks and improved 
overall health (Garg et al., 2013). Importantly, the authors also injected Mecp2 
+/-
 female mice with the virus and found that scAAV9/Mecp2 expressed 
Mecp2 at levels close to physiological level. Female scAAV9/Mecp2 injected 
mice showed improvement of symptoms such as motor functions and seizures 
and overall better health over their control injected counterparts although there 
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was no improvement in respiratory symptoms. This work is important 
clinically as the majority of human RTT patients are female and over-
expression of MeCP2 will cause neurological symptoms. 
Besides re-expression of MeCP2 to alleviate symptoms, another avenue of 
therapeutics is through drugs. A promising candidate is aminoglycosides 
which promotes read-through of premature stop codons, which affects 35 % of 
RTT patients (Percy et al., 2007). Several studies have found that 
aminoglycosides have effectiveness of 10-38% in promoting read-through of 
various MeCP2 premature stop codons (Brendel et al., 2011; Brendel et al., 
2009; Popescu et al., 2010; Vecsler et al., 2011).  
Brain Derived Neurotrophic Factor (BDNF) is a known MeCP2 target (Wang 
et al., 2006), but is poor at crossing the blood-brain barrier (BBB). Instead, 
drugs increasing the expression of BDNF such as cysteamine (increased 
vesicle secretion of BDNF) and 7,8-dihydroxyflavone (BDNF receptor 
activation) reportedly improved RTT symptoms in mouse model (Johnson et 
al., 2012; Roux et al., 2012). Insulin Growth Factor 1 (IGF1), which targets 
many similar pathways as BDNF, has been shown to be useful in relieving 
RTT symptoms in mice (Castro et al., 2014; Tropea et al., 2009) and in RTT-
patient derived neurons (ref), and has been shown to improve anxiety and 
breathing abnormalities in RTT patients in a clinical trial (Khwaja et al., 2014).  
Another approach is the use of drugs that target various neurotransmitters 
receptors. Benzodiazepine which enhances the effect of GABA could 
transiently reverse breathing abnormalities in mice (Voituron and Hilaire, 
2011). Pentobarbital which inhibits GABA receptors could restore structural 
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defects and synaptic activity in Mecp2-deficient neurons (Ma et al., 2015). 
The ampakine CX546 which activates glutamatergic receptor could restore 
respiratory behavior in Mecp2-null mice (Ogier et al., 2007). L-Dopa which 
increases dopamine levels that targets the dopaminergic system improved 
motor deficits, tremors and respiratory phenotypes of Mecp2-null mice 
(Panayotis et al., 2011; Szczesna et al., 2014). Overall, these drugs are 
promising in overcoming defects in RTT. 
1.2 Stem cells 
1.2.1 Introduction to embryonic stem cells 
In a broad sense, stem cells are unspecialized cells that can undergo self-
renewal and have the ability to differentiate into specialized cell types. In 
mammals, development begins when the oocyte is fertilized by the sperm. 
This results in the formation of the initial diploid cell known as the zygote 
(Fig 1.3). The zygote subsequently undergoes cellular division to form a ball 
of dividing cells called the morula and later, a more specialized structure 
called the blastocyst. The blastocyst contains a group of cells called the inner 
cell mass (ICM) and as the blastocyst matures, the ICM forms into two cell 
layers, the hypoblast- which forms the yolk sac, and the epiblast which forms 
the three primordial germ layers (ectoderm, mesoderm and endoderm) from 
which all fetal cells are derived. It is from the ICM of the early blastocyst that 
embryonic stem cells (ESCs) are derived (Fig 1.3). The first successful 
attempt to isolate human embryonic stem cells (hESCs) from the inner cell 
mass was in 1994 (Bongso et al., 1994). These cells however could not be 
maintained in culture for long. In 1998, hESCs were successfully derived and 
maintained in culture leading to widespread interest in the field (Thomson et 
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al., 1998). hESCs are pluripotent stem cells (PSCs) meaning they can 
differentiate into the three germ layers from which all the cells in the human 
body derive. Because of this, hESCs are seen as an attractive source for 
obtaining cells that are difficult to access from the body such as brain or heart 
cells for studies in both development and diseases. Due to their malleability, 
hESCs represent a potential source of cellular material in the field of 
regenerative medicine such as replacing defective insulin-producing cells in 
diabetes or replacing degenerated dopaminergic neurons in Parkinson’s 
disease. Despite their obvious potential in science and medical applications, 
the use of hESCs is opposed in some quarters. This is because generating 
hESCs lines requires the destruction of the blastocyst, which has the potential 
to become a human. Hence the use of hESCs has been shrouded in ethical 
controversy. 
 
Fig 1.3 Schematic of early mammalian development. Fertilisation produces 
a zygote which undergoes cleavage division to form the morula. Further 
division of the morula forms the early blastocyst which contains the ICM. The 
ICM in the late blastocyst segregates into the epiblast and the hypoblast. ESCs 





1.2.2 The advent of induced pluripotent stem cells 
It was long believed that differentiated cells could not change into another cell 
type nor revert to an undifferentiated state. This paradigm was challenged in 
1962 when John Gurdon demonstrated that a frog’s egg with its nucleus 
replaced by that of an intestinal epithelial cell could still fully develop into a 
tadpole (Gurdon, 1962) (Fig 1.4A). This method is known as somatic cell 
nuclear transfer (SCNT) and in principle, John Gurdon had shown that the 
nucleus of a differentiated cell retained the capacity of pluripotency. In 1997, 
the same principle was reenacted in mammals with “Dolly the sheep” (Wilmut 
et al., 1997). These experiments laid the belief that differentiated human cells 
too have the potential of pluripotency. In 2006, Kazutoshi Takahashi and 
Shinya Yamanaka reported that they had managed to coax mouse embryonic 
fibroblast into an undifferentiated state by viral transduction of a cocktail of 
transcription factors (Takahashi and Yamanaka, 2006). This technique was 
termed “reprogramming” and the resultant cells resembled ESCs in many 
ways including morphology, expression of ESC markers, and ability to form 
the three lineages. These ESC-like cells were called “induced pluripotent stem 
cells” (iPSCs). In 2007, the same experiments were successfully reproduced in 
human cells, thus generating the first human iPSC lines (Takahashi et al., 2007; 






Fig 1.4 Key milestones leading to reprogramming of human cells. (A) 
SCNT experiments with animal models (1) UV was used to destroy the 
nucleus in a frog egg and (2) the nucleus of the egg was replaced with a 
nucleus from an epithelial cell of a tadpole. (3) The manipulated egg was able 
to develop into an adult frog. (4) SCNT was successfully carried out in 
mammals. (B) Reprogramming using transcription factors. (1) A set of 
transcription factors was introduced into (2) mouse fibroblast resulting in (3) 
pluripotent cells capable of contributing to chimeric mice. (4) Reprogramming 
was successfully carried out in human cells. Image  adapted from (Jonas 
Frisen, 2012).  
1.2.3 The reprogramming process 
The initial experiments to generate iPSCs utilised 4 transcription factors. They 
are Oct4, Sox2, Klf4, c-Myc (OSKM) (Takahashi and Yamanaka, 2006). Oct4, 
Sox2 and Klf4 are highly expressed in ESCs and are involved in the regulation 
of other pluripotent and self-renewal genes (Boyer et al., 2005; Chew et al., 
2005; Jiang et al., 2008; Rodda et al., 2005). c-Myc is a proto-oncogene best 
known to be involved in cell cycle regulation and proliferation of tumours but 
it also plays a role in the maintenance of ESCs (Cartwright et al., 2005; 
Varlakhanova et al., 2010). Of OSKM, Oct4, Sox2 and Klf4 represent critical 
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components of reprogramming while c-Myc has been shown to be dispensible 
(Nakagawa et al., 2008; Wernig et al., 2008b). The addition of c-Myc however 
served to enhance efficiency of the reprogramming process (Nakagawa et al., 
2008; Wernig et al., 2008a). 
The molecular mechanism of reprogramming remains to be understood but 
several studies have shed light as to the role of each factor during 
reprogramming. For a somatic cell to become an iPSC, it needs to undergo 
two main phases (Fig 1.5). The first is the Mesenchymal-Epithelial Transition 
(MET) (Sancho-Martinez and Izpisua Belmonte, 2013). For facilitation of 
MET, Oct4, Sox2 and c-Myc have been found to promote the epithelial state 
by downregulating mesenchymal genes and TGF-beta receptors (Li et al., 
2010a). Klf4 activates epithelial genes including E-cadherin that gives the cell 
an epithelial identity (Li et al., 2010a). After the MET, the cell undergoes a 
second phase which is the establishment of the pluripotent circuitry. The 
individual role of OSKM in this second phase is less well understood but Oct4 
and Sox2 target genes were found to be upregulated early in this phase before 
subsequent activation of target genes by Klf4 to complete the reprogramming 
process (Polo et al., 2012). c-Myc is not thought to play a major role in the 
second phase (Polo et al., 2012; Sridharan et al., 2009). However, the role of 
each factor is highly dependent on context as sequential addition of the factors 
in the order of OK+M+S instead of simultaneous OSKM addition was found 
to result in a different gene expression profile, and also resulted in a higher 
reprogramming efficiency (Liu et al., 2013). Several other changes occur 
during reprogramming including microRNA expression and chromatin 
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modifications and these have been reviewed in several articles (Adachi and 
Scholer, 2012; Apostolou and Hochedlinger, 2013; Liang and Zhang, 2013). 
 
Fig 1.5 Molecular changes during reprogramming. Reprogramming of 
somatic cells into iPSCs entails two main “waves”. The first wave is the MET 
which gives the cell an epithelial identity. The second wave establishes 
pluripotent genes expression and gives the cell an ESC-like identity. Image 
reproduced with permission from (Sancho-Martinez and Izpisua Belmonte, 
2013). 
1.2.4 Advantages of iPSCs 
Like hESCs, iPSCs have the ability to self-renew and differentiate into the 3 
lineages. However, there are many key advantages to using iPSCs over hESCs. 
First, as iPSCs do not involve the destruction of the blastocytst, there are no 
ethical issues to overcome. Second, iPSCs derived from patients suffering 
from a genetic disorder provide a direct disease-related and genetically 
relevant source of material for research and clinical applications. Third, for 
regenerative medicine, iPSCs derived from individuals would possibly have a 
lesser chance of immuno-incompatibility when cells are transplanted into the 
same individual. While cellular transplantation using hiPSCs derived material 
still has to overcome many significant challenges (i.e. safety and efficacy) to 
be of practical use, an obvious impact of iPSCs has been disease modeling. 
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Like hESCs, iPSCs allows an indirect access to specific cell types like brain or 
heart cells that have traditionally been difficult to obtain. Using iPSCs, we can 
now generate cellular models to study genetic diseases with specific human 
cell types. The attractiveness is apparent and is evident by the large numbers 
of studies that has generated and studied disease-bearing iPSCs lines (Onder 
and Daley, 2012; Rajamohan et al., 2012). 
1.3 Neural cells 
This section gives an introduction to the main cell types investigated in this 
thesis. 
1.3.1 Neural stem cells 
The central nervous system originates from the neural plate and neural tube. 
Both the neural plate and neural tube are composed of neuroepithelial cells 
that can undergo symmetrical division. These neuroepithelial cells are the first 
neural stem cells in the developing embryo and are the precursors to the 
neurons, astrocytes and oligodendrocytes. Besides the developing brain, neural 
stem cells have also been demonstrated to be present in discrete regions of the 
mammalian adult brain, including human (Eriksson et al., 1998; Song et al., 
2002; van Praag et al., 2002). Neural stem cells from humans can be isolated 
from post-mortem fetal brain tissue or adult brain tissue but these sources are 
limited by availability of donor material (Park et al., 2012; Uchida et al., 2000; 
van Strien et al., 2014). Alternatively, iPSCs represent a useful source for NPC. 
In line with most publications, the term NPC is used here to refer to a 
heterogeneous population comprising of neural stem cells and progenitor cells 




Astrocytes are the most common glia in the CNS and derive from the neural 
stem cells of the neuroepithelia. Astrocytes perform a wide range of functions. 
One function of astrocyte is their ability to regulate neurotransmitter 
homeostasis in the brain. For example, glutamate is released during neuronal 
transmission as an excitatory neurotransmitter. However, excess glutamate is 
neurotoxic and astrocytes perform an important role in taking up excess 
glutamate to prevent neurotoxicity (Schousboe and Waagepetersen, 2005). 
Astrocytes are essential for the formation and maintenance of the Blood-Brain 
barrier (BBB). The BBB is a tightly regulated interface between the CNS and 
the vascular system that controls the movement of nutrients, ions, hormones 
and cells into the CNS. Astrocytes together with pericytes and endothelial 
cells are the 3 cell types that make up the BBB. Astrocytic endfeet are in close 
contact with endothelial cells and pericytes in the CNS and is thought to 
almost completely cover the whole blood vessel structure (Mathiisen et al., 
2010). Besides forming a physical barrier, astrocytes secrete ECM proteins 
that serves as attachment factors and signalling components of the BBB. The 
ECM also make up the basement membrane which forms additional physical 
barrier and provide physical support for the different cells types (Baeten and 
Akassoglou, 2011). BBB dysfunction has been associated with many 
pathological symptoms such as stroke, multiple sclerosis, Alzheimer’s disease 
and Parkinson’s (Abbott et al., 2006; Cabezas et al., 2014; Desai et al., 2007). 
Astrocytes are known to secrete a variety of cytokines that are related to 
inflammatory functions. For example, CXCL1, CXCL8 and CXCL10, which 
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regulate neutrophils and T cells recruitment in the CNS, are induced in 
astrocytes upon viral infection (Kutsch et al., 2000; Rubio and Sanz-Rodriguez, 
2007). Abnormal cytokine levels secreted by astrocytes such as TNF-α could 
also be a cause of neurodegeneration in Parkinson disease (Hirsch et al., 2003).  
Another important astrocyte function is supplying metabolic precursors to the 
neurons. Accumulating evidence shows that astrocytes release of lactate that is 
taken up by neurons as a metabolic substrate in times of neuronal activity 
(Brown and Ransom, 2007; Escartin et al., 2006; Figley, 2011). Disruption of 
the astrocyte-neuron lactate transport resulted in learning and long-term 
memory deficits in mice highlighting its importance in cognitive functions 
(Suzuki et al., 2011). 
These examples highlight the importance of astrocytes in brain homeostasis 
and development. Understanding astrocyte’s functions and roles in pathology 
may lead to prospective therapies in neurological diseases . 
1.3.3 Microglia 
Microglia are the innate immune cells of the CNS and play important roles in 
inflammation in response to pathogens and injuries (Streit, 1996). The brain 
has however harnessed these professional phagocytes for additional 
purposes— neuronal development and plasticity. For instance, microglia 
regulate synapse numbers by engulfing immature or weak synapses in a 
process called synaptic pruning (Paolicelli et al., 2011; Schafer et al., 2012). 
Removal of these unwanted synapses is important for brain maturation 
(Paolicelli et al., 2011), and reduced synaptic pruning can result in impaired 
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social behavior and repetitive behavior in mice (Zhan et al., 2014), much like 
some of the symptoms of RTT. Microglia also play an important role in 
clearing away apoptotic cells in the brain by phagocytosis (Ashwell, 1990; 
Marin-Teva et al., 2004), and this was shown to facilitate neurogenesis in the 
adult brain (Sierra et al., 2010). In addition, microglia can also secrete 
cytokines that regulate neurogenesis (Battista et al., 2006{Walton, 2006 
#2340). The discovery of microglia’s role beyond immunity revealed 
important ways in which neuronal development and plasticity are regulated. 





Chapter 2: Background and outline of thesis 
2.1 Background of thesis 
RTT animal models, especially the mouse, have contributed greatly to our 
knowledge of RTT. However, crucial inter-species differences exist between 
mice and humans. For instance, heterozygous female Mecp2+/- show either no 
or very mild symptoms (Guy et al., 2001). As such, the male Mecp2-/y mouse 
which shows more severe symptoms is typically used to model RTT despite 
the disease primarily affecting females in humans. This indicates that findings 
from mice might not always be translatable to humans. Hence, it is important 
to reconcile findings from mice model with human based model. It is however 
not feasible to isolate brain cells from humans, especially from that of an RTT 
patient. The use of iPSCs is therefore a viable alternative of studying RTT in a 
human context. My main hypothesis is that human iPSCs can used to model 
RTT. To test this hypothesis, I decided to generate iPSCs from patients 
carrying MeCP2 mutations. Shortly after commencing on the project, several 
publications reported the modelling of RTT using RTT patients’ iPSCs 
(Ananiev et al., 2011; Cheung et al., 2012; Kim et al., 2011; Marchetto et al., 
2011). These studies reported that iPSCs has been generated from RTT 
patients carrying MeCP2 mutations and showed that neurons generated from 
RTT iPSCs display diseased phenotypes such as reduced synapse number and 
reduced dendrite development (Marchetto et al., 2011). As the mutations I was 
studying is similar to what has been published (Marchetto et al., 2011),  I 
decided to look into how iPSCs can be used to model other aspects of the 
disease to complement the existing literature. One area lacking detailed studies 
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is the role of non-neuronal cells such as the NPCs, astrocytes and microglia in 
the pathology of RTT. Recent findings from RTT mouse models indicated that 
other brain cell types might play a role in the disease (Ballas et al., 2009; 
Maezawa and Jin, 2010; Maezawa et al., 2009; Nguyen et al., 2013). I 
hypothesize that non-neuronal cells might play a role in the pathology of the 
RTT in humans. In vitro differentiation of glia from RTT patients’ iPSCs 
would allow a system to study the role of glia in the pathology of the disease. 
Hence I decided to look further into the roles of NPCs, astrocytes and 
microglia in the pathology of RTT. More specific hypotheses and aims are 
described in the relevant chapters.  
2.2 Outline of thesis 
For my project, I aimed to model the role of NPCs, astrocytes and microglia 
by inducing iPSCs from RTT patients and differentiating these cells into the 
respective cell types. In the first part of my thesis (Chapter 4), I reprogrammed 
and characterized isogenic iPSCs from RTT patients carrying MeCP2. Chapter 
5 describes the induction of NPCs from isogenic iPSCs. The differentiation of 
neurons from the NPCs is also detailed here. In Chapter 6, I describe the 
generation of astrocytes from isogenic iPSCs-derived NPCs. The 
differentiation of microglia from iPSCs is described in chapter 7. With each 
cell type, comprehensive characterization was carried out to confirm their 
identity. Phenotypic comparisons were then carried out to identify differences 
between isogenic WT and MT cells, the results of which are detailed in the 
respective chapters. The graphical outline of this project is shown in Fig 2.1. 




Fig 2.1 Graphical representation of project outline. Fibroblasts are 
reprogrammed into isogenic iPSCs and subsequently differentiated into 
several brain cell types. Chapter 4 describes the generation of iPSCs, Chapter 
5 describes the differentiation of NPCs and neurons, Chapter 6 describes the 






Chapter 3: Materials and Methods 
3.1 Cell culture medium 
Fibroblast medium 
DMEM supplemented with 10% FBS, 2mM L-glutamine and 1% 
Penicillin/Streptomycin (all from Gibco, Life Technologies) 
iPSCs medium 
KO-DMEM supplemented with 20% KOSR, 2mM L-glutamine, 0.2mM 
NEAA, 0.1mM 2-mercaptoethanol and 5ng/ml basic Fibroblast Growth Factor 
(bFGF) 
Neural Induction Medium 
DMEM/F12 supplemented with 20% KOSR, 2mM L-glutamine, 0.2mM 
NEAA, 0.1mM 2-mercaptoethanol and 1mM Sodium Pyruvate. 
NPCs medium 
Neurobasal medium supplemented with 2mM L-glutamine, 1% B27, 1% N2 
and 20ng/ml bFGF. 
Neural differentiation medium 
Neurobasal medium supplemented with 2mM L-glutamine, 1% B27, 1% N2 




3.2 Cell culture 
MEF 
Mouse embryonic fibroblast (MEF) were plated onto gelatin coated plate and 
maintained in fibroblast medium. Cultures were passaged using trypsin at a 
ratio of 1:4-1:6 to passage 4 after which gamma irradiation was performed at 
2000 rad. The inactivated MEF were then cryopreserved. For use as feeder 
layers, inactivated MEF were plated on gelatin coated dish at a density of 
25000cells/cm2. 
Patients’ Fibroblast 
RTT patients’ fibroblasts were procured from Coriell Cell Repository. Cells 
were passaged using trypsin at a ratio of 1:2-1:5 and maintained in fibroblast 
medium. 
HEK293T 
HEK293T cells were maintained in Fibroblast medium at a density of 5 x 104 
cells/cm2. 
iPSCs and ESCs 
iPSCs and ESCs cell lines were all maintained on inactivated MEF in iPSC 
medium. Medium change was performed every day and cultures were 




Reprogramming of fibroblast 
Patient’s fibroblasts were plated at a density of 100 000 cells/well of a 6cm 
plate in fibroblast medium. 24hrs later, reprogramming viruses were added to 
cells. 48hrs later, fibroblast was trypsinised and plated onto a 100mm plate of 
MEF in fibroblast medium at a density of 100000 cells/plate. 48hrs later 
medium was changed to iPSCs medium. Colonies will appear 2 weeks later 
and were manually isolated for plating onto MEF feeder for maintenance 
under iPSCs conditions. 
In vitro embryoid body differentiation 
iPSCs were manually cut out from feeder layer and transferred to low 
attachment plate in iPSCs medium without bFGF for formation of embryoid 
bodies. After 2 weeks, EBs were attached on TC plate and cultured further for 
another 2-4 weeks. 
Generation of NPCs from PSCs 
iPSCs were manully cut out from feeder layer and dissociated into single cells 
by accutase. 10 000 cells were plated into one well of a 96-well round bottom 
low attachment plate in Neural induction medium (NIM) for formation of 
neurospheres. After 24 hours, cells aggregate into a sphere. ½ vol medium 
change was performed every 3 days and cells were left in the plate for a total 
of 7 days. Neurospheres were then attached onto laminin coated plates in NPC 
medium. Rosettes will be visible in 7-14 days and rosettes are manually cut 
out and expanded in suspension in low attachment plates. Henceforth they are 
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known as NPC and maintained in NPC medium with medium change once 
every 3 days. 
Generation of neurons from NPC 
NPC were dissociated into single cells and plated onto laminin coated plate at 
a density of 100000 cells/cm2 in NPC medium without bFGF for a period of 2- 
6 weeks. Medium was changed once every 3 days. 
Generation of astrocytes from NPC 
NPC were dissociated into single cells and plated onto laminin coated plate at 
a density of 100000 cells/cm2 in NPC medium without bFGF. Cells were 
passaged and replated every 2 weeks for a period of 90 days. Neurons were 
gently removed by pipetting. 
Generation of microglia from PSC 
At the time of writing, the method used for deriving microglia is patent 
pending. 
3.3 Teratoma formation 
iPSCs were dissociated into single cells by accutase and cells were harvested 
and counted. 3 million cells (resuspended in PBS) were injected 
intramuscularly into one thigh of a 6 week old SCID mice. Teratoma growth 
was observed every week for up to 12 weeks. Teratoma was harvested 
between 8-12 weeks by dissection, fixed in formalin and sent for histological 




Colcemid was added to actively proliferating cells overnight before sending 
samples for karyotyping analysis. Standard G-banding chromosome analysis 
was carried out in the Cytogenetics Lab at KK Women's and Children's 
Hospital of Singapore. 
3.5 Plasmids 
Reprogramming retrovirus plasmids: pMXs-hOCT3/4 (Addgene #17217), 
pMXs-hSOX2 (Addgene #17218), pMXs-hKLF4 (Addgene #17219), pMXs-
hc-MYC (Addgene #17220), pBABE-neo-hTert (Addgene #1774). 
Packaging plasmids for lentivirus: pMDLg/pRRE (Addgene #12251), pRSV-
Rev (Addgene # 12253), pMD2.G (Addgene #12259).  
A shRNA sequence against MeCP2 was cloned into the pLL 3.7 lentilox 
vector (Addgene #11795) to form the hairpin loop (5’-
GGAGGTCTTCTATCCGATCTGTTCAAGAGTCAGATCGGATAGAAGA
CCTCC-3’) (Marchetto et al., 2010). Underlined region indicates loop. 
A control shRNA sequence against LacZ was cloned into the pLL 3.7 lentilox 
vector to form the hairpin loop (5’- 
TGTGGATGGAGCCGATATTGGATTCAAGAGATCCAATATCGGCTCC





3.6 Virus preparation 
HEK293T cells were seeded at 4.5x106 cells/ 100mm plate. 24hrs later, cell 
density should be at 90-95%. Plasmid and packaging vectors were transfected 
into HEK293T cells using lipofectamine 2000 (Invitrogen) according to 
manufacturer’s instruction. 48 hours later, medium was collected from plates 
and spun at 2000rpm for 5min. Supernatant was collected and spun in an 
ultracentrifuge at 25000rpm for 2 hrs at 8oC. Virus pellets were resuspended in 
DMEM and frozen into aliquots at -80oC. 
3.7 Immunocytochemistry 
Cells were fixed in 4% paraformaldehyde for 20 mins. Permeabilisation and 
blocking was done in blocking buffer consisting of 0.1% Triton-X 100, 4% 
goat or donkey serum diluted in PBS for 30 min. Primary antibodies were 
diluted in blocking buffer and incubated overnight at 4oC. Secondary 
antibodies were diluted in blocking buffer at 1:1000 and incubated for 30 mins 
at room temperature. The list of primary antibody and dilution is provided in 




Table 3.1 List of antibodies used in immunostaining 
 
3.8 Flow cytometry 
Cells were dissociated into single cells by accutase and fixed using 
Cytofix/cytoperm reagent (BD Bioscience) for 20mins on ice. Fixed cells were 
washed with PBS and blocked with 4% goat serum for 20mins on ice. 
Incubation with primary antibody was carried out for 40mins on ice. Cells 
were washed 3x with 0.1% PBST before incubation with secondary antibody 
for 30mins on ice. Cells were washed 3x with 0.1% PBST and resuspended in 
PBS + 1% goat serum. Samples were ran through a FACScalibur and 
quantitated using Cellquest Pro software. Normalisation was done using an 
isotype control or no primary antibody control. Nestin antibody (BD #61159) 
was used at a dilution of 1:400 and GFAP antibody (Dako #Z0334) was used 




3.9 Live-cell flow cytometry sorting 
Cells were dissociated into single cells by accutase and washed twice with 
PBS and blocked with 1% BSA for 20 mins on ince. Incubation with primary 
antibody was carried out for 20mins on ice. Cells were washed 2x with PBS 
before incubation with secondary antibody for 20mins on ice. Cells were 
washed 2x with PBS and resuspended in PBS + 1% BSA and sent for live cell 
sorting. Live cell sorting was carried out at the Singapore Immunology 
Network Flow Cytometry facility. 
3.10 Luminex 
For collection of conditioned medium, NPC were plated at a density of 
cells/cm2 and astrocytes were plated at a density of 10000 cells/cm2. 
Conditioned medium (CM) was collected at 24 hours and 72 hours. Luminex 
was carried out at the Singapore Immunology Network Luminex facility. 
3.11 Glucose uptake assay 
Cells were plated at 8000 cells/cm2 overnight. The next day, cells were 
incubated with low glucose DMEM for 6hrs. Medium was removed and fresh 
low glucose DMEM with 100µM 2-(N-(7-Nitrobenz-2-oxa-1,3-diazol-4-
yl)Amino)-2-Deoxyglucose (2NBDG) (Invitrogen) was added to cells and 
incubated for the respective time. Medium was removed and cells were 




3.12 Glutamate determination assay 
Glutamate determination assay was carried out using a Glutamate assay kit 
(Biovision #K629-100) according to manufacturer’s instruction. Briefly, 100 
000 cells were plated overnight and fresh medium with100µM of L-Glutamic 
acid was added. CM was collected at the respective times and centrifuged at 
2000rpm for 5mins. Supernatant was collected and 50µL of sample was added 
to 1 well of reaction mix and incubated for 30 min at 37oC. Optical density 
was measured at 450nm in a microplate reader. Readings from triplicate wells 
were taken and averaged. 
3.13 WST-1 Proliferation assay 
Cell proliferation assay was carried out using the cell proliferation reagent 
water soluble tetrazolium salt 1 (WST-1) (Roche #05015944001) according to 
the manufacturer’s instruction. Briefly 2000 cells/ well were plated into a 96 
well plate. 10µL/well of WST-1 reagent was added and incubated for 0.5 hr in 
an incubator. Absorbance was measured using a plate reader at 480nm. 
Readings from triplicate wells were taken and averaged. 
3.14 TNFα detection assay 
100 000 cells were incubated in one well of a 12 well plate for 24 hours. CM 
was collected and TNFα detection was carried out using the Human TNFα 
ELISA Kit (Thermo Scientific #EH3TNFA2) according to manufacturer’s 
instructions.  Absorbance was measured using a plate-reader (SpectraMax M5, 
Molecular Devices). Readings from triplicate wells were taken and averaged. 
	

3.15 Phagocytosis assay 
NPCs were dissociated into single cells and stained with 5µL/mL of 5-
Carboxytetramethylrhodamine (5 –TAMRA) (Life Technologies #C-6121) for 
5 minutes. Stained NPCs were then treated with ultraviolet light in a laminar 
flow hood for 15 min and washed with PBS ( through centrifugation) before 
incubation with microglia for 5 hours.  
3.16 Migration assay 
NPCs were dissociated into single cells by accutase and 8000 cells were plated 
into one well of a 96-well low-attachment plate for formation of a neurosphere. 
24 hours later, single neurospheres were plated into one well of a 24-well plate 
coated with laminin. 24 hours later, cells were fixed and stained with nestin 
antibody. To quantify surface area, images were taken with a fluorescent 
microscope (Fig 3.1A) and converted to an 8-bit image (Fig 3.1B) using the 
Image J software. Using the “Analyse particles” function in Image J, the total 
surface area of all stained object was directly measured (Fig 3.1C). 
 
Figure 3.1 Measurement of surface area. Fluorescent image of neurosphere 
(A) is converted into an 8-bit image (B) using Image J. The surface area is 





3.17 Synapse quantification 
Neurons were plated at a density of 2000 cells/cm2 onto laminin coated glass 
cover-slips. 6-8 weeks later, neurons were fixed and stained with VGlut1, 
PSD95 and Map2 antibodies. Images of neurons were taken with a confocal 
microscope and numbers of synapse were manually counted. 
3.18 RNA isolation 
Medium was aspirated and cells were washed twice with PBS before addition 
of lysis buffer. RNA was extracted with RNeasy Mini Kit (Qiagen), according 
to the manufacturer’s instructions. DNAse I (Qiagen) was used for all 
extraction to minimize genomic DNA contamination. RNA quality and 
quantity was measured using a spectrophotometer (Nanodrop, Thermo 
Scientific). Only samples with an A260/A280 absorbance ratio greater than 
1.9 were analyzed. 
3.19 Reverse transcription 
1µg of RNA was reverse transcribed to complementary DNA (cDNA) using 
the iScript Reverse Transcription Supermix (BioRad #170-8840) according to 
the manufacturer’s instructions to a volume of 20µL. Master mixes were 
prepared for multiple reactions and incubations were carried out on a thermal 
cycler (Mastercycler, Eppendorf). 
3.20 Reverse Transcription-PCR (RT-PCR) 
RT-PCR was carried out using Platinum PCR Supermix (Invitrogen) 
according to the manufacturer’s instructions. 2µL of cDNA and 200nM of 
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primers were used and amplification was carried out on a thermocycler 
(Mastercycler, Eppendorf). PCR amplifications were performed as follows: 
1. Initial denaturation 94 oC 3 min 
2. Denaturation 94 oC 30 sec 
3. Annealing 55 oC 15 sec  
4. Extension 72 oC 1 min per Kb  
Repeat step 2 to 4 for 35 cycles  
RT-PCR products were ran on a 1% agarose gel made up with 1x TAE buffer 
and visualized using the BioRad GEL-Doc system. 
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Table 3.2 List of primers for RT-PCR and sequencing
 
3.21 Quantitative RT-PCR (qRT-PCR) 
qRT-PCR was carried out using 2µL of cDNA, 200nM of each primer and 2x 
iQ SYBR Green Mastermix (BioRad) in a 25µL reaction. Amplification and 
detection was carried out using the iQ5 real-time PCR detection system 
(Biorad). PCR amplifications were performed as follows: 
1. Initial denaturation 96 oC 3 min 
2. Denaturation 96 oC 30 sec 
3. Annealing 55 oC 15 sec 
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4. Extension 60 oC 4 min - Repeat step 2 to 4 for 40 cycles  
Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) and Beta 2 
Microglobulin (B2M) were used as endogenous controls. Relative expression 
of target genes was calculated using the comparative method (2−∆∆Ct). Melting 
curves analysis and “no template control” reactions were performed to ensure 
primer specificity. All reactions were ran in triplicates. 






PCR was carried out using 3-10ng of DNA, 10µM of primer and 8ul of 
BigDye terminator reaction mix with a volume of 20µL. PCR amplifications 
were performed as follows: 
1. Initial denaturation 96 oC 3 min 
2. Denaturation 96 oC 30 sec 
3. Annealing 50-55 oC 15 sec - Temp depends on Primer Tm, skip if Tm  
 >  60oC 
4. Extension 60 oC 4 min - Repeat from step 2 for 35 cycles for >800 bps read, 
25 cycles for <500 bps reads 
Subsequent sequencing steps were performed by the IMCB sequencing unit. 
3.23 Microarray experiments 
RNA quality control 
RNA was isolated as described in section 3.23. For further quality control, 
RNA quality was analysed using the Bioanalyzer (Agilent) according to the 
manufacturer’s instruction. Only samples with an RNA intergrity number 
(RIN) above 8 is used for microarray. 
RNA amplification 
500ng of RNA was amplified using the Illumina TotalPrep- 96 RNA 
Amplification Kit (Ambion) according to the manufacturer’s instructions. 
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Briefly, 500ng of total RNA was reverse transcribed to cDNA followed by 
second strand cDNA synthesis. Second strand cDNA was purified followed by 
in vitro transcription to complementary RNA (cRNA). cRNA was purified and 
quantified with the Nanodrop. 
Bead chip hybridization 
Briefly, 750 ng of cRNA was prepared according to manufacturer’s 
instructions and added to each sample array of the HumanHT-12 v4 
Expression BeadChip (Illumina) which targets more than 47,000 probes 
derived from the National Center for Biotechnology Information Reference 
Sequence (NCBI) RefSeq Release 38. The Beadchips was incubated for 
20hours at 58oC in a hybridization oven with rocker. Following that, the 
Beadchips washed, blocked and stained with streptavidin-Cy3 according to 
manufacturer’s instructions. Scanning was done with the Illumina BeadArray 
Reader.  
Analysis of microarray data 
The raw image signal was extracted using Illumina BeadStudio software and 
converted to .CEL files for analysis using GeneSpring GX v11.5 (Agilent). To 
identify differentially expressed genes (DEG) between 2 conditions, a 
student’s paired T-test with Benjamin-Hochberg false discovery rate (FDR) 
control (0.05) was performed. Analyses were further performed using the 
Database for Annotation, Visualisation and Integrated Discover (DAVID) 
version 6.7 (http://david.abcc.ncifcrf.gov/) (Huang da et al., 2009a, b). 
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Alternatively, additional microarray analyses for microglia data were 
performed using the Ingenuity iReport (Qiagen). 
3.24  Statistical Analysis 
The numeric data are presented as mean ± SEM. The statistical significance of 
the differences between group means was evaluated using an unpaired 
Student’s t-test. 1 way ANOVA followed by post-hoc Tukey test was 
performed for all multiple comparisons. All statistics were performed using 





Chapter 4: Reprogramming of RTT patients’ fibroblast 
4.1 Introduction  
The relatively straight forward and robust method of generating hiPSCs by 
introduction of a defined set of transcription factors has been achieved by 
several groups (Lowry et al., 2008; Park et al., 2008a; Takahashi et al., 2007; 
Yu et al., 2007). The use of hiPSCs in modeling neurological disorder for 
which brain cells are difficult to access has been a popular choice for many 
researchers (Han et al., 2011; Wang and Doering, 2012).  
However, one of the challenges in using iPSCs for disease modeling is getting 
suitable control cells. Age matched control from non-affected subjects are 
typically used but this is not ideal as variability in genetic background and risk 
factor exposure could lead to confounding results. X-linked genetic disorders 
offer the possibility of generating isogenic WT and MT iPSCs from the same 
patient. In humans, females inherit two copies of the X-chromosome from the 
paternal and maternal gametes. In a phenomenon called X chromosome 
inactivation (XCI), one copy of the X is inactivated. Both the paternal or 
maternal copy of the X can be inactivated and this process is thought to be 
random resulting in a 1:1 mixture of active paternal and maternal copy of the 
X chromosome (Ozbalkan et al., 2005). Hence it is theoretically possible to 





4.2  Hypotheses and Aims 
Female RTT patients have a mosaic of cells in which half expresses the 
wildtype (WT) copy of MeCP2 and the other half expresses the mutant (MT) 
copy of MeCP2. Due to this phenomenon, there is a possibility of getting 
isogenic iPSCs lines from the same patient in which some colonies would 
express WT MeCP2 and some colonies would express MT MeCP2. This will 
give us isogenic lines in which both WT and MT iPSCs lines would have 
identical genetic background with the exception of the viral integration site of 
the reprogramming factors OSKM and the active copy of X-Chromosome. My 
hypothesis is that isogenic iPSCs can be generated from individual female 
RTT patients. To test this hypothesis, I decided to reprogram RTT patients’ 
fibroblast using retroviral OSKM and isolate single colonies. Characterisation 
of the colonies would be carried out to confirm that the cells are pluripotent 
and karyotypically normal. Identification of the colony’s genotype would be 
carried out based on the MeCP2 mutation. These iPSCs would be used to 
generate the cell types to be studied in later chapters.  
At the time this project commenced, one group had reported the generation of 
iPSCs from RTT patients but without phenotypic investigation (Hotta et al., 
2009). During the course of this study, several other groups reported 
derivation of iPSCs from RTT patients bearing MeCP2 mutations (Ananiev et 
al., 2011; Cheung et al., 2011; Kim et al., 2011; Marchetto et al., 2010). The 





4.3.1. RTT patients’ background 
Fibroblasts from female RTT patients were purchased from Coriell Cell bank. 
GM11272 was derived from a 3 yr female Caucasian and carries a 32 bp 
deletion in position 1155 of MeCP2. This also causes a frameshift downstream 
of the deletion resulting in putative premature stop codons. This patient is 
reported to show classic RTT symptoms. Henceforth, cells and derivatives 
from this patient are referred to as P72. 
GM16548 was derived from a 5 yr female Caucasian and carries a C>T 
transition at position 730 of MeCP2. This causes a codon change from 
glutamine to termination. This patient is reported to be clinically affected with 
the following symptoms: abnormal sleep patterns; ambulatory with some 
rigidity/spasticity; slight spine curvature; breath holding; constipation; 
decelerating head circumference; limited purposeful hand use; nonverbal; poor 
hand and feet circulation; repetitive hand motions; seldom exhibits self-
injurious behavior; small feet; teeth grinding; minor eating difficulties and 
reflux; tremors; EEG shows minor abnormalities. Henceforth, cells and 
derivatives from this patient are referred to as P48. 
GM17880 was derived from a 5 yr female Caucasian and carries a C>T 
transition at position 473 of MeCP2. This results in the substitution of 
threonine by methionine at position 158 of the MeCP2 protein. This patient is 
reported to have growth and developmental delay; can walk only with 




seizures, but significantly abnormal EEG; teeth grinding; some sleep 
difficulties; eating problems with minor reflux; breath holding and 
hyperventilation; small feet; some tremor. Henceforth, cells and derivatives 
from this patient are referred to as P80. 
4.3.2. Reprogramming of fibroblast through retroviral induction 
The most commonly employed method of reprogramming is through viral 
induction of OSKM (Lowry et al., 2008; Park et al., 2008b). Therefore, we 
sought to reprogram RTT patients’ fibroblasts using retroviral induction of 
OKSM. Briefly, fibroblasts were expanded and transduced with pooled 
OSKM retrovirus particles (Fig 4.1C&D). Transduced fibroblasts were then 
trypsined and plated onto mouse embryonic feeders (MEF) (Fig 4.1E). 2 
weeks later, iPSC like colonies were manually picked and expanded on MEF 






Fig 4.1 Reprogramming of fibroblast into iPSCs. (A) Diagram of the 
MeCP2 protein showing relative position and type of mutation of the cell 
lines used in this study. (B) Schematic representation of the reprogramming 
protocol (C) Morphology of fibroblast at day 1 before transduction. (D) 
Morphology of fibroblast 3 days after viral transduction (E) Emergence of 
iPSCs-like colonies at day14 (F) Morphology of a fully reprogrammed 
colony at day 21 (G) Chosen colony is manually cut and transferred to new 
MEF plate (H) Morphology of handpicked colony at day1 after subculture. 
Scale bar represents 100 µM. 
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4.3.3. hTert can overcome skewing of reprogramming 
To identify between WT and MT iPSCs clones from P72, we designed primers 
that flanked the 32 bp deletion of the MT MeCP2. Due to a 32 bp deletion of 
MeCP2 in MT cells, PCR products were easily distinguishable on an agarose 
gel between WT and MT iPSCs due to a size difference. For P48 and P80, 
DNA sequencing was used to distinguish between WT and MT MeCP2 
expressing cells. RT-PCR of the P72 fibroblast population showed that both 
WT and MT cells are present (Fig 4.2A). Unexpectedly, we discovered that all 
iPSCs clones from P72 expressed the MT allele (Fig 4.2A). To further 
investigate, we subcloned the mixed fibroblasts from P72 and P80 into 
populations that exclusively express either the WT or MT allele only and 
reprogrammed the pure population. Alkaline phosphatase staining which is a 
marker for stem cells is used to identify iPSCs colonies. P72 MT fibroblasts 
showed a higher reprogramming efficiency than P72 WT fibroblast while on 
the other hand, P80 WT fibroblasts showed a higher reprogramming efficiency 
than P80 MT fibroblasts based on alkaline phosphate expression (Fig 4.2B). 
Subsequent experiments to investigate the cause of this unequal 
reprogramming led to the discovery that P72 WT cells entered senescence 
earlier and exhibited increased DNA Foci damage (Pomp et al., 2011b), and 
that this phenotype could be overcome by expression of exogenous human 
telomerase reverse transcriptase (hTert) (Pomp et al., 2011b). To see if hTert 
could also overcome the reprogramming roadblock of the P72 WT fibroblast, 
we used OSKM + hTert as the viral transduction cocktail. Addition of hTert 
enabled us to generate both WT and MT iPSCs clones (Fig 4.2C). For P48, we 
did not check the reprogramming efficiency for the individual WT and MT 
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populations as OSKM + hTert was directly used to reprogram a mixed culture 
of fibroblasts and we managed to get both WT and MT iPSC colonies (Fig 
4.2D). 
 
Fig 4.2 Derivation of isogenic iPSCs from RTT patients’ fibroblast. (A) 
RT-PCR results showed reprogramming using OSKM from mixed population 
of P72 fibroblast gave rise to only MT iPSCs clones. (B) OSKM 
reprogramming of subcloned fibroblast population showed presence of iPSC 
colonies as indicated by alkaline phosphatase staining in only WT population 
from P80 and in only MT population from P72. (C) RT-PCR result from 
OSKM + hTert reprogramming enabled successful reprogramming of isogenic 
clones from P72. (D) Sequencing result from OSKM + hTert reprogramming 






4.3.4 Pluripotent marker expression and transgene silencing 
Characterisation of the generated iPSCs was carried out to check for 
expression of pluripotent markers and silencing of the transgenes. Several 
lines were generated but for the purpose of this thesis, only results from iPSCs 
generated from P72 and P48 are shown. RT-PCR of endogenous expression of 
pluripotent genes such as Oct4, Sox2, Nanog and Dnmt3b was carried out and 
all iPSCs clones showed up-regulation of pluripotent markers (Fig 4.3A). 
RNA from the hESC line H9 was used as a positive control. To test for 
silencing of transgenes, RT-PCR of transgenic OSKM + hTert was carried out. 
The results showed these transgenes were silenced in the mature iPSCs clones 
(Fig 4.3B). The respective plasmid vector used for reprogramming was used 
as a positive control (1:1000 dilution). To examine if patient’s iPSCs express 
pluripotent markers at the protein level, immunofluorescence staining of Oct4, 
Sox2 and Tra 1-60 was carried out and all iPSCs clones showed strong 





Fig 4.3 RT-PCR characterisation of iPSCs. (A) iPSCs clones generated 
showed expression of endogenous pluripotent markers. (B) iPSCs clones 






Fig 4.4 Characterisation of the iPSCs lines. Immunofluorescence of iPSCs 
lines P48 and P72 showing expression of the pluripotent markers Oct4, Sox2 
and Tra1-60. Scale bar represents 100µM. 
4.3.5  In vitro differentiation of iPSCs 
An important aspect of pluripotency is the ability to generate the three germ 
layers. To test for this ability in the generated iPSCs, in vitro differentiation 
was carried out. This is done through formation of embryo-like aggregates 
termed embryoid bodies (EBs). EBs recapitulate several aspects of early 
development and all three embryonic germ layers are present (Itskovitz-Eldor 
et al., 2000). Briefly, undifferentitated iPSCs were cut into pieces and cultured 
in suspension to allow for formation of 3-D spheroid structures (Fig 4.5A-D). 
EBs formed by 3-5 days and cystic EBs formed after 2 weeks of 
differentiation. Plating of EBs onto gelatin coated plates resulted in attachment 
and outgrowth of heterogenous cell types (Fig 4.5E&F). Immunofluorescence 
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of the differentiated cells showed presence of the three germ layers. The 




                    
 
 





Fig 4.5 in vitro differentiation of iPSCs lines. Formation of EBs. (A) 
Morphology of undifferentiated iPSCs. (B) iPSCs colony is manually cut into 
pieces. (C) iPSCs in suspension form EBs after 48 hours. (D) EB showing 
cystic structure. (E) and (F) Spontaneous differentiation of attached EBs 
showed heterogenous morphology and cystic structures. 
Immunocytochemistry of EBs from iPSCs of (G) P48 and (H) P72 showed 
presence of the three germ layers: fetoprotein and vimentin (endoderm), β-III-
tubulin and GFAP (ectoderm) smooth muscle actin and desmin (mesoderm). 
Blue staining represents Hoescht. Scale bars represent 100µM. 
 
4.3.6 in vivo differentiation of iPSCs 
To further confirm the pluripotency of the iPSCs lines, in vivo differentiation 
was carried. This is done through transplantation of undifferentiated iPSCs 
into immune-compromised mice. This results in the formation of a teratoma 




germ layers (Thomson et al., 1998). Sections of teratomas showed presence of 
the three germ layers (Fig 4.6A&B).                     
 
 
Fig 4.6 in vivo differentiation of iPSCs lines. Teratomas from iPSCs of (A) 
P48 and (B) P72 showed formation of the three germ layers 6-8 weeks after 




4.3.7 Karyotypic analysis of iPSCs 
Cytogenetics analysis was carried out using karyotype analysis. This technique 
utilises Giemsa staining following cell arrest in the metaphase stage and any 
chromosomal abnormalities can be observed under a microscrope. All iPSCs 
generated showed normal karyotype (Fig 4.7). 
 
Fig 4.7 Cytogenetics analysis of iPSCs lines. Karyotype analysis of iPSCs 
lines from P48 and P72 showed normal XX karyotype at passage 10. 
 
4.3.8 Detection of MeCP2 in iPSCs 
To examine if iPSCs express MeCP2 protein, immunofluorescence using an 
antibody able to detect N-terminal MeCP2 was performed. The ESC line H9 
was used as a positive control and showed clear nuclear staining of MeCP2 
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(Fig 4.8A). However, both WT and MT iPSCs do not show distinct nuclear 
MeCP2 staining (Fig 4.8B&C).. Instead, a diffuse staining pattern was 
observed on the iPSCs colonies while surrounding MEF showed clear nuclear 
staining. To further confirm this result, a control iPSCs line from a non-
affected subject (a kind gift from a colleague, Zhou Fan) was used and the 
same non-specific staining was observed (Fig 4.8D). 
 
Fig 4.8 Expression of MeCP2 in PSCs. Immunofluorescence of MeCP2 
staining in (A) H9 showed distinct nuclear expression while (B) WT and (C) 
MT iPSCs derived from P72 and (D) control iPSCs do not show expression of 







4.4.1. The role of TERT in reprogramming 
Telomeres are repetitive nucleotide sequences at the ends of chromosomes that 
protect chromosomes from deterioration or recombination with neighbouring 
chromosomes (Blackburn, 2001). However, each cell replication cycle results 
in shortened telomeres and shortened telomeres is associated with cellular 
senescence and organismal aging (Allsopp et al., 1995; Blasco, 2005). In 
mammals, one way of telomere length maintenance is through telomerase- a 
ribonucleoprotein structure consisting of TERT and TERC (Telomere RNA 
component). TERT functions as a reverse transcriptase at the ends of 
chromosomes to add repeat sequences to compensate for telomeres shortening 
during mitosis (Greider and Blackburn, 1985) while TERC acts as an RNA 
template for TERT. Telomerase activity is present in indefinitely replicating 
cells such as ESC and immortal cancer cells (Hiyama and Hiyama, 2007; Kim 
et al., 1994), but is absent in most somatic cells which eventually leads to 
shortening of  telomeres and cellular senescence (Allsopp et al., 1995; Blasco, 
2005). It has been reported that iPSCs have high telomerase activity and cells 
from telomerase-deficient mice with critically shortened telomeres showed 
lower reprogramming efficiency and reintroducing of telomerase could restore 
reprogramming efficiency (Marion et al., 2009). 
In this study, we successfully generated isogenic iPSCs from RTT patients’ 
fibroblast. Using the commonly employed virus mix OSKM, we report that 
only one fibroblast population could be induced into iPSCs. Further 
investigation into this phenomenon showed that the fibroblast population that 
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had low reprogramming efficiency showed increased DNA damage and 
underwent senescence earlier than fibroblasts with normal reprogramming 
efficiency. As telomeres are involved in cell proliferation and DNA repair, and 
telomere length has been correlated with reprogramming efficiency (Marion et 
al., 2009), we hypothesized that addition of exogenous hTert could lead to 
DNA repairs and restoration of telomere length, which in turn will lead to 
recovery of reprogramming efficiencies. Hence the cell population with low 
reprogramming efficiency could be improved. However, cells with normal 
reprogramming efficiency do not see an improvement possibly because hTert 
do not improve reprogramming beyond its role of DNA damage and 
overcoming cell senescence.  Introduction of hTert together with OSKM 
yielded  iPSCs expressing either WT MeCP2 or MT MeCP2. At this point, we 
speculate that the mechanism behind this skewing is X-linked polymorphism 
(Pomp et al., 2011a). Together, our findings highlight the significance of 
telomere biology in iPSCs generation. 
During the course of this study, several groups reported derivation of iPSCs 
from RTT patients bearing MeCP2 mutation (Ananiev et al., 2011; Cheung et 
al., 2011; Kim et al., 2011; Marchetto et al., 2010). There are however, 
inconsistencies in the X-Chromosome status of the iPSCs as reported by the 
various groups (Table 4.1). Marchetto et al., 2010 reported getting biallelic 
iPSCs and that subsequent differentiation of the iPSCs resulted in random XCI 
of the progeny cell (Marchetto et al., 2011). Kim et al., 2011 reported getting 
iPSCs that are either biallelic or monoallelic (Kim et al., 2011). Cheung et al., 
2011 and Ananiev et al., 2011 reported getting monoallelic iPSCs clones 
which our supports our data (Ananiev et al., 2011; Cheung et al., 2011). The 


cause for the inconsistency remains unknown but one possibility is that the 
type of feeders used in generating iPSCs could be a factor in determining X-
Chromosome status (Tomoda et al., 2012). 
Table 4.1. X-Chromosome status of iPSCs reprogrammed from RTT patients 
from various groups 
 
4.4.2. Characterisation of iPSCs 
Exhaustive characterization of the iPSCs lines was carried out and both WT 
and MT iPSCs generated showed similar features to hESC including cell 
morphology and expression of pluripotent markers. The pluripotency of the 
iPSCs was demonstrated by both in vitro and in vivo differentiation through 
the presence of the three germ layers of endoderm, mesoderm and ectoderm. 
No difference was detected between WT and MT iPSCs. In addition, OSKM 
and hTert transgenes expression were silenced and iPSCs showed normal 
karyotypes. In summary, the iPSCs generated fulfilled the criteria of PSC and 
there was no difference between WT and MT iPSCs. This is in line with the 
other reports. As our results showed, MeCP2 is either not translated or is 
expressed at very low levels in iPSCs though it has a higher expression in 





In summary, I described the generation of isogenic WT and MT iPSCs lines 
from RTT patients. Reprogramming of fibroblasts showed bias and this could 
be overcome by exogenous hTert expression. Isogenic lines are genetically 
very similar and represent a good model for disease modeling. Later chapters 
will describe the use of these lines for modeling RTT. 
4.6. Limitations 
4.6.1 Characterisation of more patients’ iPSCs. 
The results here showed the characterization of P72 and P48 iPSC WT and 
MT lines. However, iPSCs from P80 were not completed in time for this thesis 
due to the length of time needed to carry out the characterization.  
4.6.2 Retroviral-based reprogramming 
The iPSCs generated in this project were done using integrating viral vectors 
and is currently the most widely used technique due to its high efficiency. 
However, this method might introduce mutations at the transgene integration 
site and other genetic aberrations (Laurent et al., 2011). Several strategies have 
been developed to generate transgene free iPSCs. These include non-
integrating Sendai viruses (Fusaki et al., 2009), episomal vectors (Yu et al., 
2009), mRNA based reprogramming (Warren et al., 2010) and protein based 
reprogramming (Kim et al., 2009; Zhou et al., 2009). These methods will 
minimize variations due to reprogramming process and create better quality 
and more consistent iPSCs lines. Another strategy would have been to induce 

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the mutation in normal stem cells and to correct the mutation in MT cells by 
molecular gene editing (e.g. using CRISPR-CAS9 system (Hsu et al., 2014)).  
4.6.3 MeCP2 expression in iPSCs 
In section 4.3.8, MeCP2 immunostaining was shown to be present in the 
hESC line H9 but the staining was weak and diffuse in iPSC lines. Hence, the 
result is inconclusive and a western blot should be done to further confirm the 
expression level of MeCP2 in iPSC lines. An iPSCs specific marker such as 
Tra1-60 should also be used to better distinguish between the iPSC colonies 
and MEF in Figure 4.8. However, these experiments were not conducted in 




Chapter 5: Investigating the role of NPCs in RTT using iPSCs 
5.1 Introduction 
The majority of early RTT research was focused on neurons as initial studies 
in mice demonstrated the critical role of Mecp2 in neurons. Knocking out 
Mecp2 in post-mitotic neurons was enough for RTT symptoms to manifest in 
mouse (Chen et al., 2001), while re-expression of Mecp2 in post-mitotic 
neurons of Mecp2-null mice was able to effect a rescue of the RTT phenotype 
(Luikenhuis et al., 2004). Afflicted neurons show several morphological 
phenotypes including reduced dendritic arbors (Kishi and Macklis, 2004), 
smaller soma and nucleus size (Chen et al., 2001) and reduced excitatory 
synapse number (Chao et al., 2007). Afflicted neurons also showed abnormal 
electrophysiological properties such as abnormal long term potentiation 
(Asaka et al., 2006; Moretti et al., 2006). These findings and the absence of 
MeCP2 expression in glia led to the belief that RTT is an exclusively neuronal 
disorder (Kishi and Macklis, 2004; Shahbazian et al., 2002b). It was only in 
recent years that new evidences revealed the involvement of the other brain 
cell types such as astrocytes, microglia and oligodendrocytes in RTT 
pathology (Ballas et al., 2009; Maezawa and Jin, 2010; Nguyen et al., 2013). 
RTT is largely seen as a disorder of post-natal maturation. The age of onset of 
RTT symptoms in human (6-18 months) and mice (6 weeks) coincides with 
the period of neuronal maturation, and this is supported by the progressively 
higher expression of Mecp2 as neurons mature (Kishi and Macklis, 2004; 
Shahbazian et al., 2002b). However, the neo-natal fatalities and severe 
infantile encephalopathy of human males with MeCP2 mutations suggest an 
	
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early brain developmental role of MeCP2. Furthermore, in Xenopus laevis 
embryos, silencing of Mecp2 resulted in early neuronal patterning defects 
(Stancheva et al., 2003). These evidences suggest MeCP2 may have a role in 
the early development of the CNS. 
5.2 Hypotheses and Aims.  
During CNS development, NPCs arising from the neural tube proliferates, 
migrate and further differentiate into neurons and glia. The main purpose of 
this study was to test the hypothesis that NPCs may represent a cell type that is 
affected in RTT. As there are no in-depth studies of the role of NPCs in RTT, I 
decided to look at how MeCP2 mutations can affect NPCs’ properties. One 
property I wanted to investigate is proliferation. Microcephaly is a symptom 
associated with RTT and one cause of microcephaly is reduced proliferation of 
the NPCs. My hypothesis is that NPCs affected by MeCP2 mutations could 
show reduced proliferation. To test this hypothesis, a proliferation assay will 
be carried out comparing the growth rate of WT and MT NPCs. 
Another aspect I wanted to look at is migration. NPCs are highly migratory 
cells as shown during both brain development (Doetsch and Alvarez-Buylla, 
1996; Halliday and Cepko, 1992; Merkle and Alvarez-Buylla, 2006), and 
during brain pathology (Imitola et al., 2004; Jeon et al., 2008; Shah et al., 
2005). As several neurological disorders including autism and schizophrenia 
are found to have abnormality in neuronal migration (Wegiel et al., 2010; 
Yang et al., 2011). I was interested to see if NPCs are affected in their 
migratory property. To test this hypothesis, a migration assay will be carried 




The third aspect I wanted to test is the differentiation potential of the NPCs to 
neurons. As brains of RTT patients and mouse models show immature 
neuronal development (Chao et al., 2007; Francke, 2006), I wanted to examine 
whether MeCP2 mutations affect neuronal development. To test this 
hypothesis, I intend to compare neuronal differentiation between WT and MT 
NPCs and also the maturity of the respective neurons based on synapse 
numbers. 
5.3 Results 
5.3.1 Derivation of NPCs from iPSCs 
WT and MT iPSC lines from P72 were used to derive NPCs with the “serum-
free embryoid body” (SFEB) method with modifications (Eiraku et al., 
2008)(Fig 5.1A). This method is based on the default model of neural 
induction which states that embryonal cells acquire a neural identity in the 
absence of signaling instructions, hence “by default” (Hemmati-Brivanlou and 
Melton, 1997) (Tropepe et al., 2001) (Reubinoff et al., 2001). We chose this 
method as it mimics the in vivo development of the neural system and is 
defined compared to the stromal cell induction system. Briefly, iPSCs were 
dissociated into single cells and allowed to form EB cell aggregates under 
defined condition (Fig 5.1B-D). Adhesion of EBs to the plastic dish in the 
presence of FGF2 led to the formation of rosette-like structures after 2-3 
weeks of neural induction (Fig 5.1E). Neural rosettes are radially organized 
columnar epithelial cells that resemble the neuroepithelial cells in the neural 
tube (Zhang et al., 2001). The neural rosettes can then be manually isolated 
and further expanded as NPCs in the presence of FGF2 (Fig 5.1F&G).  
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To validate that cells generated were NPCs, immunocytochemistry was 
performed using 2 widely used NPCs markers– nestin and sox2 (Ellis et al., 
2004; Reubinoff et al., 2001; Zhang et al., 2001). Immunocytochemistry 
showed that the iPSCs-derived NPCs stained strongly for these 2 markers (Fig 
5.2A). These results showed that both WT and MT iPSCs could generate. To 
see if NPCs express MeCP2, we performed immunocytochemistry using an 
antibody specific to a sequence at the N-terminal of MeCP2. Both WT and 
MT NPCs showed positive staining demonstrating that MeCP2 is expressed in 
NPCs (Fig 5.2A). FACS using nestin antibody was carried out to measure the 
purity of the NPCs and the data show that both WT and MT iPSCs generated 
NPCs equally well (Fig 5.2B). RT-PCR showed that the respective NPCs 
retained their active X-chromosome expression (Fig 5.2C).  These results 




Figure 5.1 Derivation of NPCs from iPSCs (A) Schematic of NPCs 
induction from iPSCs. (B-G) Representative images of NPC induction 
protocol at different stages, (B) day 0– iPSCs (C) day 1– aggregation of single 
cells in round bottom well (D) day 2– formation of embryoid body (E) day 
14– formation of rosettes (F) day 17–expansion of NPCs in suspension or (G) 




Fig 5.2 Characterisation of iPSCs-derived NPCs. (A) 
Immunocytochemistry showing positive staining with antibodies targeting 
Nestin, Sox2 and MeCP2 for both WT and MT NPCs. Scale bar represents 
100µM. (B) FACS showing high percentage of nestin-positive cells for both 
WT and MT NPCs. Purple histograms represent no-primary antibody control 
while green histograms represent cells incubated with antibody. (C) RT-PCR 








5.3.2 Comparison of NPCs proliferation rate 
Both human RTT patients and mouse models show microcephaly (Chen et al., 
2001; Hagberg, 1995). One main cause of microcephaly in general is reduced 
proliferation of NPCs (Woods et al., 2005). We wanted to see if MeCP2 
deficiency would affect NPCs proliferation. Cell proliferation assays were 
carried out using water-soluble tetrazolim salt 1 (WST-1) assay. This method 
is based on the enzymatic cleavage of WST-1 by viable cells to form a 
colorimetric dye as a proxy of cell number. Our results showed no significant 
differences in the proliferation rate between WT and MT NPCs (Fig 5.3). This 
suggests proliferation of NPCs is not likely to be the cause of microcephaly in 
RTT.   
 
Fig 5.3 Proliferation rate of WT and MT NPCs. WST1 proliferation assay 
of WT and MT NPCs over 7 days. 
5.3.3 iPSCs-derived NPCs show defect in cell migration 
As cell migration is an important aspect of NPCs during brain development 
and abnormal migration is the cause of many brain disorders (Valiente and 
Marin, 2010), we wanted to determine if cell migration is affected in MT 
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NPCs. Neurospheres (aggregates of NPCs) of equal size were made and 
attached onto laminin coated plate. After 24 hours, the amount of migration 
was measured. We consistently observed a higher rate of distant migration in 
WT neurospheres compared to MT neurospheres (Fig 5.4A).  
To confirm this phenotype was caused by deficiency of MeCP2, we performed 
RNA silencing of MeCP2 in WT NPCs using a shRNA specific to MeCP2 
(Marchetto et al., 2010). Silencing of MeCP2 caused a reduction of the 
migration rate of WT neurosphere compared to a control shRNA with a 
scrambled sequence (Fig 5.4B). We further performed RNA silencing of 
MeCP2 in H9-derived NPCs and observed the same phenotype (Fig 5.4C). 







Fig 5.4 Migration rate of NPCs. (A-C) Left panel- Representative images of 
respective neurospheres before attachment and 24hrs after attachement, Right 
panel- graphical representation of respective neurospheres of surface area 
24hrs after attachment (Mean + SEM, n=6, * p-value <0.05, ** p-value <0.01, 
unpaired t-test) .  Efficiency of MeCP2 silencing in (D) WT iPSCs-derived 
NPCs and (E) H9-derived NPCs (Mean + SEM, ** p-value <0.01, unpaired t-









5.3.4 Non-cell autonomous effect of NPCs 
As the human female RTT brain consists of a mix of WT and MT cells, we 
wanted to model the physiological cellular make-up by mixing WT NPCs with 
MT NPCs. We labeled WT NPCs with a red fluorescence protein (m-cherry) 
and MT NPCs with a green fluorescence protein (GFP), and mixed equal 
numbers of labeled WT and MT NPCs to form single neurospheres. We 
wanted to see whether cellular migration rates were affected by the mixing of 
WT and MT cells. In particular, we wished to see if the presence of the WT or 
MT NPCs influenced the migration rate of the other population. There could 
be four possible scenarios— the mixed cells will migrate: 1) similar to the MT 
cells, 2) have an intermediate migration rate, 3) similar to the WT and 4) the 
WT cells migrate faster leaving behind the MT cells (Fig 5.5A). 
Mixing of WT and MT cells resulted in scenario 2 in which there is an 
intermediate rate of migration demonstrated by both cell types (Fig 5.5B&C). 
We also did not observe WT NPCs showing higher migration rate than MT 
NPCs in the mixed neurosphere (Fig 5.5D). This indicates that there is a non-






Fig 5.5 Coculture of WT and MT NPCs. (A) Mixture of WT-mCherry (red) 
and MT-GFP (green) NPCs into single neurospheres could show four different 
scenarios, 1. same size as MT only, 2. intermediate size between MT and WT, 
3.  same size as WT only or 4. WT cells moving at a faster rate compared to 
MT cells. (B) Representative images showing migration rate of WT, mixed 
and MT NPCs stained with DAPI. (C) Graphical representation of the 
migration rate of the three cell types (n=6, * p-value <0.05, ** p-value <0.01, 
*** p-value <0.001, 1-way ANOVA with post-hoc Tukey test). (D) Mixed 









5.3.5 Gene expression array of NPCs 
The presence of MeCP2 as seen in immunostaining of NPCs indicates that 
MeCP2 might have a role in gene regulation (Fig 5.2A). Therefore, we carried 
out gene expression microarray to identify if there was any difference between 
WT and MT NPCs.  The gene expression study of NPCs generated from 
isogenic iPSCs provided many valuable insights into the possible functions of 
MeCP2 in human NPCs. Analysis of the microarray signals revealed a list of 
598 differentially expressed genes (DEG) (P-value <0.05; absolute fold 
change >2) (Appendix 1). Hierarchical clustering of the 598 DEG was 
performed to give an overview of relative expression value among the samples 
(Fig 5.6). The heat map generated revealed consistent gene expression patterns 
in WT NPCs versus MT NPCs, illustrating the reproducibility of the 
expression data (Fig 5.6). Of the 598 DEG, 283 genes were upregulated in MT 
NPCs while 315 genes were downregulated (Appendix 1). The top 15 up-
regulated and down-regulated genes are shown in Table 5.1 and Table 5.2. 
The finding of both up- and down-regulation of transcripts support the 
evidence that MeCP2 can act as both a transcriptional repressor and activator 





Fig 5.6 Heat map cluster analysis of microarray. 598 DEGs were identified 
between WT and MT NPCs 
Table 5.1 Top 15 differentially up-regulated genes in MT iPSCs-derived 





Table 5.2 Top 15 differentially down-regulated genes in MT iPSCs-
derived NPCs based on fold change. 
 
To validate the results of the microarray, real-time PCR of selected genes of 
interest including Transmembrane protein 132D (TMEM132D), Contactin 6 
(CNTN6), Sodium Channel, voltage-gated, type II alpha subunit (SCN2A) and 
Homeobox B8 (HOXB8) was carried out (Fig 5.7). The result showed 
consistency with the microarray results (Table 5.3). A gene ontology (GO) 
analysis using DAVID Functional Annotation was performed (Huang da et al., 
2009b). GO analysis (P-value <0.05) showed an enrichment of GO terms 






Fig 5.7 Real-time PCR validation of expression microarray. Each graph 
represents the relative fold difference of MT NPCs compared to WT NPCs 
(mean+SEM, * p-value<0.01, ***p-value<0.001, unpaired t-test). 
Table 5.3 Comparison of microarray and real-time PCR fold changes of 
selected genes. Values are expressed as MT/WT fold change, with positive 
value denoting up-regulation and negative value denoting down-regulation in 
MT NPCs. 
 
Table 5.4 Top 5 GO terms under biological processes identified among 
differentially expressed genes based on p-value using DAVID. 
 
5.3.6 Neuronal differentiation of NPCs 
It was reported in the RTT mouse model that Mecp2 deficient neurons showed 
reduced excitatory synapse numbers (Chao et al., 2007). We wanted to see if 
MT neurons could recapitulate this phenotype. To generate neurons, we 
carried out spontaneous differentiation of the NPCs by withdrawal of bFGF 
from the culture medium. Under this condition, NPCs generated cells with 
neuronal morphology with positive β-tubulin III immunostaining (Fig 5.8A). 
Both WT and MT NPCs were able to generate neurons at similar efficiencies 
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(Fig 5.8B). These results demonstrate that both WT and MT NPCs from P72 
were able to generate neurons. 
To check for synapse numbers, we stained our iPSCs-derived neurons with an 
excitory pre-synaptic marker, vGlut1 and a dendritic marker, Map2 and 
quantified the numbers of vGlut1 puncta. We found that similar to the mouse 
model, MT neurons displayed reduced synapse numbers (Fig 5.8C&D). These 
results demonstrated that human iPSCs could recapitulate the neuronal 
phenotype seen in the mouse model. Together with findings from mouse 
studies (Chao et al., 2007) and human iPSCs models (Marchetto et al., 2010), 
these results support the evidence that MeCP2 regulates glutamatergic synapse 
density. 
 
Fig 5.8 Differentiation of NPCs into neurons (A) Representative images 
βIII-tubulin staining of WT and MT neurons. (B) Patch-clamp 
electrophysiology showed action potential in both WT and MT neurons. (C) 
Graphical representation of efficiency of differentiation of WT and MT NPCs 
into neurons (mean + SEM, unpaired t-test). (D) Representative images of WT 
and MT neurons stained with Map2 and vGlut1 (E) Graphical representation 
of synapse number counted in WT and MT neurons (mean + SEM, ** p-





5.4.1 iPSCs from RTT patients can be induced into NPCs and neurons 
Disorders affecting brain development have been modeled mainly in mouse 
due to the difficulty in getting human neuronal cells. However, differences 
between the mouse and human brain may not lead to faithful recapitulation of 
development and diseases (Fietz and Huttner, 2011; Lui et al., 2011). To 
circumvent these hurdles, we attempted to model RTT using iPSCs. However, 
it was unknown if iPSCs with MeCP2 deficiency could be induced into NPCs 
and differentiated into neurons. In this chapter, I describe the generation of 
NPCs from isogenic WT and MT iPSCs from a RTT patient. We used the 
SFEB method which is well-defined and follows the in vivo development 
pattern. Both WT and MT iPSCs can generate NPCs with equal efficiency. 
During the course of this study, several publications came out detailing the use 
of iPSCss to study RTT (Ananiev et al., 2011; Cheung et al., 2011; Kim et al., 
2011; Marchetto et al., 2010). These studies report the successful generation of 
NPCs from RTT iPSCs confirming our result that MeCP2 is not involved in 
NPCs formation. However, none of these studies examined the NPCs in detail. 
We therefore took the opportunity to further investigate the effects of MeCP2 
deficiency in NPCs. 
5.4.2 MT NPCs show migratory defects 
Both WT and MT NPCs proliferated equally well, but we found that MT 
NPCs did not migrate as well as WT NPCs. During brain development, neural 
stem/progenitor cells undergo several steps, including migration and 
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positioning before they establish the proper connections to form the mature 
brain. Migration is thus an important process of brain development. Our 
finding that NPCs showed reduced migration demonstrates a cellular 
mechanism that may occur in RTT NPCs. 
While this has not been shown, one possible way migration defects in NPCs 
could affect RTT patients is through structural malformation of the brain. 
Structural brain defects are not seen in female RTT patients, but a post-
mortem brain study of a male subject with a MeCP2 mutation, presenting with 
severe neonatal encephalopathy showed polymicrogyria (Geerdink et al., 
2002). In this case, structural defects may be more apparent in males due to 
our observation that in a mixed culture of WT and MT NPCs, the migration 
rate of mixed NPCs is increased indicating that non-cell autonomous effects 
are incurring. This might allow female patients to compensate for the 
migration defect to a certain extent. This also provides a reasonable 
explanation of why males with MeCP2 mutations show early and severe 
defects in brain functions as they lack this compensatory mechanism. Non-cell 
autonomous effects in MeCP2 deficiency cells have been reported in other cell 
types. For example, mice WT neurons showed abnormal dendritic arborisation 
when grown in an environment consisting of Mecp2-null neurons (Belichenko 
et al., 2009; Kishi and Macklis, 2010). In female RTT patients, WT neurons 
were also noted to have lower expression of MeCP2 compared to non-affected 
control subjects (Braunschweig et al., 2004). Mice WT astrocytes also showed 
reduced Mecp2 levels when co-cultured with Mecp2-null astrocytes (Maezawa 
et al., 2009). These findings and our observation of non-cell autonomous 
effects in NPCs highlights the significance of X-chromosome skewing ratio. 
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These evidences suggest that treatment or recovery of a percentage of afflicted 
cells may be enough to have an effect and have important implications for 
RTT patients.  
It is also not known if defects in NPC migration would lead to defective 
neuronal migration. As NPCs are precursors to neurons, they represent a 
different developmental stage to that of neurons. If NPCs’ positioning in the 
brain is affected, then it is reasonable to assume that the neurons position 
will be affected too.  However, there is no evidence of this. But abnormal 
neuronal migration has been shown to be affected in RTT rodent models of 
CDKL5 deficiency (Chen et al., 2010a; Ricciardi et al., 2012). Mutations in 
CDKL5 lead to neurological symptoms that resembles RTT suggesting that 
CDKL5 and MeCP2 may have overlaps in the same pathway/s (Archer et al., 
2006; Scala et al., 2005; Tao et al., 2004; Weaving et al., 2004). Silencing of 
CDKL5 in rodent NPCs has been shown to result in delayed neuronal 
migration in cortical regions of both embryonic brain and post-natal day 0 
pups brain suggesting deficiencies of CDKL5 affects early brain 
development (Fig 5.9) (Chen et al., 2010a; Ricciardi et al., 2012). In 
agreement, RTT patients with CDKL5 mutations typically show early-onset 
seizures in the first three months after birth indicating early brain 
dysfunction.  Our observations support the evidence that migration 




Fig 5.9 Migration defects in CDKL5 mouse model of RTT. Neural 
progenitors electroporated with a shRNA against CDKL5 displayed a delayed 
migration of neurons from the ventricular zone/ subventricular zone (VZ/SVZ) 
into the intermediate zone (IZ) and cortical plate (CP). (Right panel) 
Exogenous expression of WT CDKL5 was able to partially rescue this 
phenotype. Image reproduced with permission from (Chen et al., 2010a). 
5.4.3 Gene expression study revealed several genes differentially 
regulated in MT NPCs 
Our gene microarray results revealed several differences between WT and MT 
NPCs and provide a few clues as to what could be behind the migration 
abnormality observed. For example, the contactin protein, CNTN6 (up in MT), 
is a neural cell-adhesion molecules in which a gain of CNTN6 copy number 
variation (CNV) was found in ASD patients (van Daalen et al., 2011; Zuko et 
al., 2013). A mouse model of autism in which the contactin associated protein, 
CNTNAP2 was knocked-out displayed neuronal migration abnormality 
(Penagarikano et al., 2011). This indicates that the contactins and their 
associated proteins play crucial roles in migration and ASD. Another gene, 
DLX5 (down in MT) has been reported to be involved in migration of neurons 
in which DLX5/6 double knock-out mouse showed reduced migration of 
interneurons (Wang et al., 2010). DLX5/6 has been reported to be regulated by 
MeCP2 (Horike et al., 2005; Miyano et al., 2008), although there have been 
conflicting findings (Schule et al., 2007).  
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Besides genes involved in migration, other genes were identified that have 
links to autism and/or RTT-related neurological symptoms. TMEM132D (up 
in MT) encodes for a transmembrane protein that has been found to be 
upregulated in patients with anxiety disorder though the function of the protein 
remains unknown (Erhardt et al., 2011). Both RTT patients and mouse model 
have been reported to show heightened anxiety (Mount et al., 2002; Ren et al., 
2012; Sansom et al., 1993). Another target identified, SCN2A (down in MT), 
encodes a sodium channel subunit which has been implicated in overlapping 
RTT symptoms such as epilepsy, ASD and stereotypic behavior (Kearney et 
al., 2001; Weiss et al., 2003). The HOXb8 gene has been reported to be 
expressed in the neural tube (Deschamps and Wijgerde, 1993) and Hoxb8 
mouse knockout has been observed to exhibit self-injurious behavior caused 
by compulsive grooming (Chen et al., 2010b; Greer and Capecchi, 2002). 
Self-injurious behavior has been observed in RTT patients (Iwata et al., 1986; 
Oliver et al., 1993) while compulsive grooming has been observed in a RTT 
mouse model (Chao et al., 2010). Further investigation of these genes may 
help us understand the molecular targets of MeCP2. 
We further performed pathway analysis to identify what biological processes 
might be affected. The pathway studies show enrichment of pathway relating 
to neuronal differentiation and development. A closer look at the genes behind 
these pathways included a number of genes that are involved in neural 
progenitor movement such as C-X-C motif chemokine 12 (CXCL12) (Holgado 
et al., 2013), L1 cell adehesion molecule (L1CAM) (Kishimoto et al., 2013; 
Tonosaki et al., 2014), GATA binding protein 2 (GATA2) (Willett and Greene, 
2011) and Neurogenin 2 (NEUROG2) (Heng et al., 2008). While these genes  
		

remain to be validated, they support the notion that MeCP2 is involved in the 
early stages of neuronal development, especially migration. Further studies on 
these target genes could help us to understand the role of NPCs in RTT.  
5.4.4 MT neurons have reduced synapse numbers 
We further demonstrated that both WT and MT NPCs can be differentiated 
into neurons. In the mouse model, neurons showed reduced synapse numbers 
(Chao et al., 2007). We attempted to recapitulate the phenotype using iPSCss 
and showed that MT iPSCs-derived neurons display a similar reduction of 
synapse phenotype. This result supports similar findings from another iPSCs 
study (Marchetto et al., 2010). In contrast, we did not observe a reduced 
differentiation to neurons as reported by (Kim et al., 2011). One reason could 
be the different quality of iPSCs obtained as explained in section 4.4.1. 
5.5 Conclusions 
In summary, I described the induction of NPCs from isogenic iPSCss from a 
RTT patient. MT NPCs showed a reduced migration rate. Gene expression 
array of NPCs identified several novel genes that may be involved in RTT. 
Neurons differentiated from MT NPCs showed reduced synapse density.  
5.6 Limitations 
 
5.6.1 More patients’ samples needed 
Only iPSC lines from P72 were used here. RTT patients differ from one 
another in the range and severity of symptoms. These differences partially 




backgrounds (i.e. modifier genes). Since the finding in this thesis may 
represent the disease in one patient, it would be beneficial to reproduce these 
experiments in iPSCs lines from additional patients. The strategy was to first 
determine the phenotype to be studied using iPSC lines from one patient 
before extending the findings to other patients. However, the experiments 
from more patients (P48 and P80) could not be completed in time for this 
thesis.  
5.6.2 Rescue of migration phenotype 
The results in section 5.3.3 showed that MT NPCs had a slower migration rate. 
This phenotype was replicated when MeCP2 was silenced in WT NPCs and 
H9 hESC line. To further confirm that this phenotype is caused by MeCP2, a 
rescue experiment of MT NPC using exogenous WT MeCP2 should be 
performed. However, this experiment was not performed in time for this thesis. 
 
5.6.3 Non-cell autonomous effect of NPCs 
Section 5.3.4 showed that a mixture of WT and MT NPCs resulted in an 
intermediate migration rate between that of pure WT and pure MT NPCs. An 
important control for this experiment is to do a reciprocal experiment to label 
MT NPCs with mCherry and WT NPCs with GFP. Also, a mix of WT/WT 
cells and MT/MT cells is important to ensure that the phenotype observed is 
not due to non-specific effects caused by labelling of the NPCs. However, 
these controls were not performed in time for this thesis. 
 
As WT and MT NPCs are labeled accordingly with red and green fluorescent 




the sphere as depicted in Figure 5.5A. Hence, for this part, we did not do an 
in-depth quantification of the migration rate. However, further quantification 
of the migration rate is possible by measuring the direct distance of individual 
WT (blue line) or MT cells (white line) from the center of the sphere (Fig 




Figure 5.10 Measurement of migration rate. The distance migrated by 
different cell populations can be measured by measuring the distance of the 
individual WT (blue line) or MT (white line) cells from the center of the 





Chapter 6: Investigating the role of astrocytes in RTT using iPSCs 
6.1 Introduction 
Early studies of RTT were focused on neurons as astrocytes were not found to 
express Mecp2 (Kishi and Macklis, 2004; Shahbazian et al., 2002b). This 
notion was challenged when improved sensitivity in immunostaining methods 
detected the presence of Mecp2 in rodent astrocytes and that they could play a 
role in RTT pathology (Ballas et al., 2009; Maezawa et al., 2009; Nagai et al., 
2005). Ballas et al., 2009 reported neurotoxic effects of astrocytes isolated 
from Mecp2-null mice when co-cultured with WT hippocampal neurons (Fig 
6.1A&B)(Ballas et al., 2009). Further investigations revealed that conditioned 
medium (CM) from Mecp2-null astrocytes had the same detrimental effects 
and that a mixture of CM from Mecp2-null and WT astrocytes could not 
abrogate this effect (Fig 6.1C). This suggested the presence of one or more 
neurotoxic factors secreted by Mecp2-null astrocytes.  
 
Figure 6.1 Mouse model of RTT astrocytes. (A) WT neurons develop 
elaborate dendrites in CM from WT astrocytes. (B) WT neurons showed 
stunted dendritic growth in CM from Mecp2-null astrocytes. (C) WT neurons 
showed stunted dendritic growth in CM mixed from WT and Mecp2-null 
astrocytes. 
Maezawa et al., 2009 similarly reported that astrocytes from Mecp2-null mice 




Mecp2-null astrocytes also showed reduced proliferation, had lower BDNF 
expression and abnormal cytokine secretions. Curiously, the authors observed 
that co-culture of WT astrocytes with Mecp2-null astrocytes led to reduction 
of Mecp2 levels in WT astrocytes. They hypothesized that the presence of 
Mecp2-null astrocytes mediated a reduction of Mecp2 levels in WT astrocytes 
and showed that gap junctions played a role in mediating this reduction. This 
suggested a non-cell autonomous effect of astrocytes in which MT astrocytes 
reduced the levels of Mecp2 in WT astrocytes. 
The role of astrocytes in the pathology of RTT was further highlighted in a 
KO mouse model in which Mecp2 expression was inducible only in astrocytes 
(using a GFAP promoter) in an otherwise global KO (Lioy et al., 2011). 
Induction of Mecp2 expression in astrocytes led to increased longevity (>2.5x 
longer), better overall health score, increased movement and reversal of 
respiratory ailments (Lioy et al., 2011). In the same study, the converse mouse 
model in which Mecp2 was deficient only in astrocytes resulted in mice with 
smaller body size, clasped hindlimb phenotype and respiratory abnormalities 
though other RTT phenotypes such as lifespan, movement and anxiety related 
behaviours were not affected (Lioy et al., 2011). These findings demonstrated 
that astrocytes alone can contribute to the RTT pathology in mouse. 
6.2 Hypotheses and Aims  
The studies in the mouse model suggested that astrocytes play a role in the 
pathology of RTT. However, due to inter-species differences between mouse 
and human, it remained unclear if human RTT astrocytes also contribute to 




pathology of the disease. To investigate this further, I decided to develop a 
protocol to differentiate astrocytes from human iPSCs. To determine the 
astrocytic identity, markers and functional assay would be carried out. 
Studies in mice indicated that medium conditioned from MeCP2-null 
astrocytes resulted in stunted growth of neurons. As astrocytes play important 
roles in the regulation of the inflammation status of the brain through 
secretions of cytokines, my hypothesis is that astrocytes could contribute to 
sub-optimal neuronal health through abnormal secretion of cytokines. To test 
this hypothesis, I decided to collect conditioned medium from both WT and 
MT iPSC-derived astrocytes and measured their cytokine levels to determine 
if cytokine levels are different between the two. 
Another important astrocyte function is in the regulation of brain metabolic 
functions. Astrocytes are known to take up glucose and convert it to lactate as 
an energy supply to neurons. Hence deficiencies in these functions could result 
in suboptimal neuronal function. My hypothesis is that MT astrocytes could 
contribute to RTT pathology through deficiencies in support of brain 
metabolic functions. To test this hypothesis, I decided to test if glucose uptake 
is affected in MT astrocytes. 
To further shed light on the possible effects of MeCP2 mutations on astrocytes, 
I decided to look at the gene expression of WT astrocytes vs MT astrocytes. 
My hypothesis is that MeCP2 being a transcriptional regulator, have an effect 
on astrocytes’ gene expression. To test this hypothesis, I decided to carry out a 






6.3.1 Derivation of astrocytes from human iPSCs 
WT and MT iPSC lines from P72 were used to derive astrocytes. Due to the 
lack of established protocols for deriving astrocytes from iPSCs at the time 
this project commenced, a novel protocol was developed (Fig 6.2A). First, the 
NPCs described in chapter 5 were allowed to undergo spontaneous 
differentiation by withdrawal of bFGF. In the early phase, NPCs differentiated 
mainly into neurons with few astrocytes around (Fig 6.2B&C). Due to the fact 
that neurons are post-mitotic cells and astrocytes are proliferative cells, long 
term culture of these cells will result in expansion of astrocytes without 
corresponding increase in neuronal numbers. As neurons are less adhesive 
than astrocytes, gentle pipetting resulted in detachment of neurons while 
astrocytes remained attached (Fig 6.2D-F). Using this method, homogenous 
populations of astrocytic-like cells were derived and expanded (Fig 6.2G). 
Both WT and MT NPCs were able to generate astrocytes. This indicated that 







   
Fig 6.2 Derivation of astrocytes from iPSCs. (A) Schematic of astrocyte 
differentiation from NPCs. (B-G) Representative pictures of cells at various 
stages of the protocol with (B) day 0 showing undifferentiated NPCs (C) day 7 
showing differentiation of NPCs into mainly neurons, (D) day 90 showing 
mixture of neurons (red arrows) with astrocytes (yellow arrows). (E) and (F) 
Neurons can be gently detached leaving behind patches of astrocytes. Red 
broken line depict border of neuron detachment. (G) Pure population of 







6.3.2 Characterisation of iPSCs-derived astrocytes 
To confirm the astrocytic identity of these cells, immunocytochemistry was 
carried out using 2 commonly used astrocyte markers, GFAP and S100β  
(Brozzi et al., 2009; Raponi et al., 2007; Reubinoff et al., 2001; Zhang et al., 
2001). Both WT and MT astrocytes showed strong immuno-reactivity to 
GFAP and S100β although MT astrocytes appear to have less GFAP+ve cells 
(Fig 6.3A). However, this could be due to a lower proliferation rate (see 
section 6.3.3) as  flow cytometry showed a high percentage of the isolated cell 
population was GFAP positive (Fig 6.3B).  
To determine if the iPSC-derived astrocytes are functional, we carried out a 
glutamate uptake assay as glutamate uptake is a key characteristic of 
astrocytes (Schousboe and Waagepetersen, 2005). 100µM of glutamate was 
added to astrocyte cultures and the amount of glutamate remaining was 
measured over a three hour period. Both WT and MT iPSC-derived astrocytes 
showed an ability to take up glutamate and we did not observe a significant 
difference between the two (Fig 6.3C). This indicates that iPSC-derived 
astrocytes are functional and MT astrocytes derived from P72 do not show a 






   
 
Figure 6.3 Characterisation of iPSCs-derived astrocytes. (A) 
Immunocytochemistry of WT and MT iPSCs-derived astrocytes showed 
positive GFAP and S100b staining. (B) FACS showed high percentage of 
GFAP positive cells (C) Glutamate uptake assay showed both WT and MT 
iPSCs-derived astrocytes were able to take in glutamate over a 3 hr time 
period (mean + SEM, n= 3, * p-value <0.05, 1-way ANOVA with post-hoc 





6.3.3 Proliferation and metabolic profile of iPSCs-derived astrocytes 
During the course of maintaining the astrocytes, it was observed that MT 
astrocytes proliferated at a slower rate compared to WT astrocytes. To 
investigate further, a WST-1 proliferation assay was performed. This assay is 
based on the cleavage of the stable tetrazolium salt WST-1 by metabolically 
active cells to form a colourimetric reaction. The results showed that MT 
astrocytes proliferated at a slower rate compared to WT astrocytes (Fig 6.4). 
This appeared to be an astrocyte specific phenotype as no differences were 
observed in the respective NPCs (see chapter 5).  
WST1 proliferation assay
 
















Fig 6.4 Proliferation assay of astrocytes. MT astrocytes showed reduced 
proliferation compared to WT astrocytes. 
 
We next looked at astrocyte energy metabolism. The brain is a high energy-
consuming organ. It takes up 20% of total body energy in a resting state 
despite being only 2% of total body weight. Glucose is regarded as the main 
energy source for the brain (Sokoloff, 1977), and increasing evidence show 





as a metabolite substrate in times of neuronal activity (Chuquet et al., 2010; 
Pellerin et al., 1998; Rouach et al., 2008). As astrocytes play an important role 
in neuronal metabolism, we wanted to see if MT astrocytes are abnormal in 
this aspect. 
We looked at the glucose uptake capability of the astrocytes. To compare 
glucose uptake between WT and MT astrocytes, a fluorescent glucose analog 
2-(N-(7-Nitrobenz-2-oxa-1,3-diazol-4-yl)Amino)-2-Deoxyglucose (2-NBDG) 
was used. 2-NBDG was added to astrocyte culture and incubated for ½ - 2 
hours before performing flow cytometry. Fluorescence intensity corresponds 
directly to uptake of 2-NBDG levels in this assay. ½ hour incubation showed 
WT astrocytes displaying higher fluorescence intensity compared to MT 
astrocytes (Fig 6.5A). This indicates that WT astrocytes internalized a higher 
amount of 2-NBDG in that time. A longer incubation time 1 and 2 hours 
showed overlapping FACS histogram profiles indicating that both WT and 
MT astrocytes took in an equal amount of 2-NBDG (Fig 6.5B). These results 
showed that both WT and MT astrocytes could take in glucose but MT 
astrocytes displayed an initial delayed response compared to WT astrocytes. 





Fig 6.5 FACS profile of 2-NBDG uptake by astrocytes. (A) Experiment 1; 
Control shows WT astrocytes (green) and MT astrocytes (purple) having same 
amount of background fluorescence before addition of 2-NBDG , ½ hr 
incubation with 2-NBDG resulted in WT astrocytes showing higher 
fluorescence compared to MT astrocytes. (B) Experiment 2; Incubation of 2-
NBDG for ½ hour reproduced the same result as in experiment 1. Further 
incubation for 1 hour and 2 hours showed WT and MT astrocyte having 
almost over-lapping fluorescence profile. 
6.3.4 Cytokine profiling of astrocyte 
Astrocytes play a key role in neuroinflammation through secretions of 
cytokines (Aloisi et al., 1995; Lieberman et al., 1989). Hence, we decided to 
carry out cytokine profiling of the iPSCs-derived astrocytes to see if MT 
astrocytes are abnormal in cytokine secretions. Cytokine detection typically 
relies on the ELISA method but the Luminex platform offers several 
advantages such as improved sensitivity, multiplexing and comparatively 
higher throughput (Burkert et al., 2012; Elshal and McCoy, 2006). We 
therefore decided to assess the cytokine profiles of astrocytes using the 
Luminex platform. To determine the levels of cytokines secreted by astrocytes, 
CM from astrocyte culture was collected after 24 hours of culture. To ensure 
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equal cell numbers, cell number was determined before and after medium 
collection. Non-conditioned medium was used to normalize for background 
levels. 
The secretion levels of 14 cytokines were investigated (Table 6.1). These 
cytokines were selected based on whether they are known to be secreted by 
primary astrocytes. Of the cytokines, MCP-1, M-CSF and PDGF-AA were 
found to highly secreted (>100 pg/mL) (Table 6.2). Fractalkine, GRO, IL-8, 
IP-10, Lif, SCF and VEGF were moderately secreted (1-30 pg/mL).  The rest 
of the cytokines (IL-10, IL-17, MIP-1A and TNF-α) were undetectable. This 
could be due to the conditioning time being too short or that the iPSCs-derived 
astrocytes do not secrete these cytokines. 




Among the secreted cytokines analysed, M-CSF showed lower levels in MT 
astrocyte (p-value 0.005) (Fig 6.6). Other notable differences included iL-8, 
Fractalkine, SCF and VEGF (Table 6.2). However, as the detected levels were 
quite low (<10 pg/mL), these differences were not considered meaningful. We 
therefore decided to increase the amount of time for conditioning the medium 
to 72 hours to see if the previously undetected cytokines would be detected 
and if a longer conditioning time might reveal further differences. 
Table 6.2. Fold differences of cytokines at 24 hours between WT and MT 







Fig 6.6 Cytokine profiling of WT and MT iPSCs-derived astrocyte at 24 
hours. MT astrocyte showed significantly lower M-CSF level (mean + SD, n= 
2, ** p-value <0.01, unpaired t-test).  
At 72 hours, cytokines that were not detected at 24 hours remained undetected 
(IL-10, IL-17, MIP-1A and TNF-α) (Table 6.3). This could mean that either 
the iPSCs-derived astrocytes do not secrete these cytokines under the 
condition used or that the detection method is incompatible with this assay. 
Comparatively, MCP-1, M-CSF and PDGF-AA again showed high levels 
(>300 pg/mL) and the rest of the detectable cytokines (Fractalkine, GRO, IL-8, 
IP-10, Lif, SCF and VEGF) showing moderate levels (<100 pg/mL) (Table 
6.3). At 72 hours, MT astrocytes showed significantly higher PDGF-AA levels 
(p-value 0.007) while fractalkine level was lower (p-value 0.02) (Fig 6.7).  
Although some other cytokines showed differences in MT astrocyte, they 
either did not reach statistical significance (IP-10, M-CSF, VEGF), or the 
levels detected were too low (<20 pg/mL) (GRO, iL-8, SCF) and not 
considered meaningful. The higher level of PDGF-AA (pro-inflammatory) and 
lower level of fractalkine (anti-inflammatory) suggest that MT astrocyte might 




Table 6.3. Fold differences of cytokines at 72 hours between WT and MT 




Fig 6.7 Cytokine profiling of WT and MT iPSCs-derived astrocyte at 72 
hours. MT astrocytes showed abnormal levels of Fractalkine and PDGF-AA 
but not M-CSF (mean + SD, n= 2,* p-value <0.05, ** p-value <0.01, unpaired 
t-test).   
6.3.5 Gene expression array of astrocytes 
Previous gene expression studies have been performed on the astrocytes of 
RTT mouse model due to the lack of human material (Okabe et al., 2012; 
Yasui et al., 2013). These studies identified differences in gene transcript 
expression of astrocytes from the RTT mouse model indicating that at least in 
mouse, Mecp2 has a role in astrocyte’s transcription.  Here, we performed 
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microarray expression analysis on pure population of human astrocytes 
comparing isogenic WT and MT cells. The gene expression study of astrocyte 
generated from RTT iPSCs-derived astrocytes provided many valuable 
insights into the possible functions of MeCP2 in human astrocytes.  
Analysis of the microarray signals revealed a list of 590 differentially 
expressed genes (DEG) (P-value <0.05; absolute fold change >2) (Appendix 
2). Hierarchical clustering of the 590 DEG was performed to give an overview 
of relative expression value among the samples (Fig 6.8). The heat map 
generated revealed consistent gene expression patterns in WT astrocytes 
versus MT astrocytes, illustrating the reproducibility of the expression data. Of 
the 590 DEG, 325 genes were upregulated in MT while 265 genes were 
downregulated (Appendix). The top 15 up-regulated and down-regulated 
genes are shown in Table 6.4 and 6.5. Both up- and down-regulation of 
transcripts were observed supporting the finding that MeCP2 can act as both a 






Fig 6.8. 6 Heat map cluster analysis of microarray. 590 DEGs were 
identified between WT and MT astrocytes 
 
Table 6.4 Top 15 differentially up regulated genes in MT iPSCs-derived 







Table 6.5 Top 15 differentially down regulated genes in MT iPSCs-
derived astrocyte based on fold change. 
 
A gene ontology (GO) analysis using DAVID was performed (Huang da et al., 
2009b). GO analysis (P-value <0.01) showed an enrichment of GO terms 
relating to cell adhesion and blood vessel development (Table 6.6). To 
validate the results of the microarray, Real-time PCR of selected genes 
including TMEM132D, Growth Associated Protein 43 (GAP43), 4-
aminobutyrate aminotransferase (ABAT), Protocadherin 5 and 19 (PCDHB5 
and PCDH19) was carried out. Real-time PCR results showed consistency 
with the microarray results in terms of up or down-regulation. Through this 
microarray experiment, we identified a number of candidate genes with a 
potential relevance for regulating astrocyte functions, which provide new 




Table 6.6 Top 10 GO terms under biological processes identified among 





Fig 6.9 Real-time PCR of selected genes. Each graph represents the relative 
fold difference of MT astrocytes compared to WT astrocytes (normalized to 1). 
(mean+SEM, * p-value<0.01,*p-value<0.001 ***p-value<0.0001, unpaired t-
test) 
 
Table 6.7 Comparison of microarray and Real-time PCR results of 
selected genes. Values are expressed as MT/WT fold change, with positive 









6.4.1 RTT patient’s iPSCs can generate astrocytes  
Once thought of as nothing more than “glue”, astrocytes have emerged as an 
important cell type that plays multiple roles in the CNS. Our understanding of 
astrocytes functions have mainly come from rodent as human astrocytes are 
hard to access. However, human astrocytes have been shown to have distinct 
properties from rodent astrocytes such as a higher propagation rate of calcium 
signaling (Han et al., 2013). iPSCs represents a potential unlimited source for 
generating human astrocytes and one aim of this study was to assess the 
usefulness of human iPSCs as a tool for getting human astrocytes. In this 
chapter, I described a robust and reproducible protocol to generate astrocytes 
from iPSCs. A unique feature of deriving astrocytes using this method is that it 
recapitulates the developmental sequence of astrogenesis in the human brain. 
In the developing brain, astrogenesis follows neurogenesis which means that 
the majority of astrocytes are formed in the presence of neurons (Kanski et al., 
2014; Liu and Zhang, 2011; Molofsky et al., 2012). The protocol developed in 
this thesis mirrors the in vivo development of the brain, in which neurons are 
first generated followed by astrocytes. Importantly, iPSCs-derived astrocytes 
showed typical astrocytic morphology, had strong expression of astrocyte 
markers, exhibit secretions of cytokines known to be secreted by astrocyte and 
were functional in terms of glutamate uptake. These results indicate iPSCs 
represents a viable way to get astrocytes from human. Furthermore, we found 
that iPSCs from P72 can be differentiatied to astrocytes. Together with reports 
from another study in which astrocytes are derived from RTT iPSCs (Williams 
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et al., 2014), this indicates that iPSCs from RTT patients represents a viable 
method for obtaining astrocytes for the study of RTT.  
A recent study reported the generation of astrocytes from RTT patients’ iPSCs 
(Williams et al., 2014). In that study, the authors generated astrocyte 
progenitor through prolonged culture (up to 300 days) of the NPCs using EGF 
and FGF as growth factors before differentiation of the progenitor into 
astrocytes. High numbers of s100β and GFAP positive cells were reported. 
They found MT iPSCs-derived astrocytes and their CM had adverse effects on 
neuronal morphology and electrophysiological functions in co-culture, 
supporting what was uncovered in the RTT mouse model (Ballas et al., 2009; 
Maezawa et al., 2009). Our findings corroborate the finding that RTT iPSCs 
can generate astrocytes. We went on to study several aspects of astrocyte 
functions including proliferation, metabolism, maintenance of glutamate 
homeostasis, cytokine secretions and gene expression in a bid to uncover 
possible mechanisms behind astrocyte pathology in RTT.  
6.4.2 Use of iPSCs-derived astrocytes for cytokine profiling 
Astrocytes are important modulators of the CNS homeostasis through 
secretions of cytokines (Aloisi et al., 1995; Lieberman et al., 1989). Recent 
studies investigating human astrocyte cytokine secretions have used astrocytes 
isolated from human fetal brain tissue which is an extremely limited source 
(Choi et al., 2014), or astrocytes derived from Ntera2, an embryonal 
carcinoma cell line that is karyotypically abnormal (Burkert et al., 2012). In 
this study, we showed that iPSCs-derived astrocytes secrete high levels of 
MCP-1, M-CSF and PDGF-AA, and moderate levels of fractalkine, GRO, IL-
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8, IP-10, Lif, SCF and VEGF. These results indicate that iPSCs-derived 
astrocyte are functional in terms of cytokine secretion and are a useful tool for 
studying cytokine secretions. This is the first study looking at cytokine 
profiling of human iPSCs-derived astrocytes to the best of my knowledge.  
6.4.3 MT astrocytes show abnormal cytokine profile 
We investigated the levels of 14 cytokines and found MT astrocytes secreted 
abnormal levels of 2 cytokines. One of them is PDGF-AA with MT astrocytes 
showing ~8-fold increase. PDGFs are growth factors that play significant roles 
in cell growth and blood vessel formation. PDGFs exist as homo- or hetero-
dimers of disulfide-linked polypeptide chains and the four PDGF family 
members include PDGF-A, PDGF-B, PDGF-C and PDGF-D (Andrae et al., 
2008). Two PDGF receptors (PDGFR) are known, PDGFR-α, of which is the 
receptor for PDGF-AA (Shim et al., 2010), and PDGFR-β. Both PDGFRs can 
activate several signaling pathways including RAS-MAPK, PI3K and PLC-γ 
(Andrae et al., 2008).  
One known consequence of increased PDGF levels in the brain is the 
disruption of the BBB through activation of PDGFR-α (Ma et al., 2011; Su et 
al., 2008; Yao et al., 2011). Disruption of the BBB results in uncontrolled flux 
of molecules, ions and immune cells across the BBB and has been implicated 
in neuroinflammation, seizures and autism (Cabezas et al., 2014; Theoharides 
and Zhang, 2011). Studies have shown that interference of PDGFR signaling 
with neutralizing antibodies or with an inhibiting compound, imatinib, has 
been shown to enhance BBB integrity and reduce neuroinflammation in mouse 
models of brain haemorrhage and multiple sclerosis (Adzemovic et al., 2013; 
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Ma et al., 2011). Interestingly, PDGF-B was found to be increased at the 
transcript level of RTT mouse astrocyte (Yasui et al., 2013), and in humans, 
PDGF-BB levels have been shown to be increased in serum levels of autism 
patients (Kajizuka et al., 2010). These findings suggest regulation of PDGF 
level or PDGFR-α activation could be a potential therapeutic for RTT. 
The other cytokine with abnormal levels is fractalkine (1.6x down in MT). 
Fractalkine is a transmembrane protein in which the extracellular domain is 
digested by protease to produce a soluble form. The sole receptor for 
fractalkine in the CNS is CX3CR1, and is reported to be expressed exclusively 
on microglia (Cardona et al., 2006; Harrison et al., 1998; Liang et al., 2009), 
although others report that CX3CR1 is also expressed in neurons (Deiva et al., 
2004; Meucci et al., 2000). In neurons, fractalkine has been reported to have a 
direct neuroprotective effect through inhibition of NMDA-mediated apoptosis 
(Deiva et al., 2004; Meucci et al., 2000). In microglia, lack of CX3CR1 led to 
increased microglia-mediated neurotoxicity in mouse model of ALS and 
Parkinson’s disease indicating that fractalkine acts to suppress microglia 
mediated neurotoxicity (Cardona et al., 2006; Pabon et al., 2011). Microglia 
lacking CX3CR1 also showed less process dynamic and migration, and 
decreased synaptic pruning (Liang et al., 2009; Paolicelli et al., 2011). These 
evidences suggest fractalkine have important anti-inflammatory and neuro-
developmental roles. Here, MT astrocytes secreting less fractalkine suggests 
that in RTT, there may be a reduction of direct neuroprotective effect, and 
increased microglia induced neurotoxicity and reduced synaptic pruning. The 
implications of abnormal microglia activity are further discussed in chapter 7.  
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6.4.4 Gene expression study revealed several genes that are 
differentially expressed in MT astrocytes 
The microarray results presented here is the first genome wide gene 
expression screen for MeCP2 target genes in human astrocytes. A previous 
microarray study identified Mecp2 target genes in mouse astrocytes but not in 
human (Yasui et al., 2013). Between the mouse and human studies, several 
related genes were found to be differentially expressed. In the mouse, APOC2, 
C3, FZD5, IGFBP4, ITGA1 were up-regulated while we found up-regulation 
of similar class of genes such as APOBEC, C5, FZD6, IGFBP7, ITGA4 in our 
iPSCs model. In the mouse, PCDH17, TM4SF1 and TSPAN13 were down-
regulated while PCDH17, TM4SF1, TM4SF18 AND TSPAN2 were down-
regulated in our iPSCs model. These findings imply that similar pathways may 
be affected in both mouse and human astrocytes and it will be of further 
interest to pursue these genes. 
Furthermore, the microarray data identified several genes of interest that are 
implicated in neurological disorders. For example, GAP-43 (up in MT) is a 
cytoplasmic protein involved in neurite formation and neurotransmission, and 
has been implicated in autism (Allen-Brady et al., 2009; Zaccaria et al., 2010). 
ABAT (up in MT) is an enzyme involved in catabolism of GABA and has been 
implicated in mental retardation and reported as autism candidate genes 
(Barnby et al., 2005; Szatmari et al., 2007). PCDHB5 and PCDH19 (both 
down in MT) belong to the protocadherin family which are important proteins 
involved in cell adhesion and signaling pathways of the nervous system (Chen 
and Maniatis, 2013; Ye and Jan, 2005). Several of the protocadherin genes 
including PCDH19 have implicated in ASD and epilepsy (Anitha et al., 2013; 
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Dibbens et al., 2008; Tsai et al., 2012). These genes however are not well 
studied in astrocytes and the finding that these genes are differentially 
expressed in MT astrocytes implies that astrocytes play important roles in 
ASD. Further studies on these set of genes in astrocytes could help us 
understand how astrocytes influence RTT. 
We further performed pathway analysis between WT and MT astrocytes and 
found that the pathways enriched are those involved in blood vessel function, 
cell adhesion and ECM. Astrocytes play important roles in the formation and 
maintenance of the BBB. Loss of cell adhesion and ECM components in 
astrocytes could lead to loss of close contact with blood vessels and a 
breakdown of the BBB (Baeten and Akassoglou, 2011; Baumann et al., 2009; 
Scholler et al., 2007). These findings further support our hypothesis that BBB 
could be affected in RTT (Fig 6.10). 
 
Fig 6.10 Proposed model of dysfunctional astrocytes on the BBB in the 
RTT brain. (A) In a healthy brain, astrocytic endfeet completely surround the 
blood vessel and form tight cell-cell adhesion with each other, with pericytes 
and with the BM thus forming an effective barrier. (B) In the RTT brain, loss 
of cell-cell and cell-ECM adhesion and loss of BM lead to breakdown of the 
BBB. Increased PDGF secretion by astrocytes further contributes to BBB 
leakiness. Image adapted from (Baeten and Akassoglou, 2011). 
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6.4.5 MT astrocytes showed abnormalities in proliferation rate 
In our study, we observed proliferation difference between isogenic WT and 
MT astrocytes but not in isogenic iPSCs lines (chapter 4) or NPCs lines 
(chapter 5). This could indicate that MeCP2 affect proliferation in specific cell 
types, and in this case, astrocytes. MeCP2 has previously been reported to 
reduce proliferation in lymphocytes from RTT patients (Balmer et al., 2002), 
and mesenchymal stem cells isolated from a RTT patient (Squillaro et al., 
2012; Squillaro et al., 2008). Silencing of MeCP2 has also been observed to 
cause a decrease in cell proliferation in the neuroblastoma line, SK-N-BE(2)-C 
(Squillaro et al., 2012), murine fibroblast line, NIH-3T3 and transformed 
human prostate cell lines, PC-3 and LNCaP (Babbio et al., 2012). 
Furthermore, a reduced proliferation rate was also reported in astrocytes 
isolated from Mecp2-null mice (Maezawa et al., 2009). However, another 
mouse study did not observe astrocyte growth retardation (Okabe et al., 2012) 
and differences in astrocytic proliferation were not reported by (Williams et 
al., 2014) in their iPSCs-derived astrocytes. One reason for the differing 
results between Williams et al., 2014 and ours could be the different strategy 
used in generating astrocytes. (Williams et al., 2014) generated astroglia 
progenitors from NPCs while we made use of the astrocytes innate 
proliferative capacity and bypassed the progenitor stage. This could result in 
our astrocytes having undergone more cell cycles and having a more “mature” 
phenotype and hence manifestation of premature senescence. Another possible 
reason could be that the iPSCs used carried different mutations (Williams et 
al., 2014).  
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6.4.6 Metabolic function of MT astrocytes is altered 
Here, we report that MT astrocytes displayed an initial delayed response 
towards glucose uptake when exposed to a glucose analog. Over a prolonged 
time however, MT astrocytes showed similar glucose uptake capacity as WT 
astrocytes. An initial delay in the glucose uptake capacity of MT astrocytes 
may mean that MT astrocytes are unable to respond quickly to support high 
neuronal energy demand during times of neuronal activity (Fig 6.11). In the 
literature, RTT patients have been reported to show both increased and 
decreased glucose metabolism depending on brain region (Villemagne et al., 
2002). However, this study was performed in sedated patients and may not 
reflect the true brain glucose utilization during neuronal activity. This work is 




Fig 6.11 Proposed model of glucose uptake deficiency in RTT astrocytes. 
(A) In a healthy brain, glucose is taken up by astrocyte and converted to 
lactate as a form of metabolic substrate taken up by neurons according to the 
lactate shuttle hypothesis. (B) In the RTT brain, delay in glucose uptake leads 
to reduced production of lactate and reduced energy supply to neurons (picture 
modified from Felipe et al., 2012). 
 
6.4.7 Role of astrocytes in RTT and neurological diseases 
Astrocytes fulfill several functions in the CNS and disruptions in any 
astrocytic functions can cause neurological symptoms. For example, excess 
glutamate released from astrocytes was found to induce seizure in a rodent 
epilepsy model (Perez et al., 2012), and astrocytes from Huntington’s disease 
mice models were found be deficient in regulating K+ homeostasis (Tong et al., 
2014). In our RTT model, we found MT astrocytes have abnormal cytokine 
secretion, retarded energy metabolics, reduced proliferation and abnormal 
gene expression. We proposed that MT astrocytes lead to disruption of the 
BBB, increase neuroinflammation and negatively impact brain energy 
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metabolics. As astrocytes are important players in regulating brain 
homeostasis, we propose that regulation of astrocyte function would be a 
promising approach to treating neuropathology and RTT. Future work to 
investigate and prove these hypotheses may lead to novel strategies in 
targeting RTT. 
6.5  Conclusions  
In summary, I have described the generation of astrocytes from isogenic iPSCs 
from a RTT patient. MT astrocyte showed reduced proliferation and delayed 
glucose uptake. Cytokine profiling demonstrated cytokines dysregulation in 
PDGF-AA and fractalkine and gene expression array identified blood vessel, 
cell adhesion and ECM functions are affected in MT astrocytes.  
6.6 Limitations 
6.6.1 More patients’ samples needed 
Only iPSC lines from P72 were used here. RTT patients differ from one 
another in the range and severity of symptoms. These differences partially 
stem from differing mutations of the MeCP2 gene and different genetic 
backgrounds (i.e. modifier genes). Since the finding in this thesis may 
represent the disease in one patient, it would be beneficial to reproduce these 
experiments in iPSCs lines from additional patients. The strategy was to first 
determine the phenotype to be studied using iPSC lines from one patient 
before extending the findings to other patients. However, the experiments 





6.6.2 Primary cells as positive controls 
While the cells derived show expression of astrocyte markers and is able to 
take up glutamate, a positive control using primary cells is needed for 
important measurements such as glutamate and glucose uptake. Primary 
astrocytes could be isolated from mouse brain as a control (Kim and Magrane, 
2011; Schildge et al., 2013). 
6.6.3 Expression of MeCP2 in iPSC-derived astrocytes 
While mouse astrocytes have been shown to express Mecp2 (Ballas et al., 
2009; Maezawa et al., 2009), it is important to show that iPSC-derived 
astrocytes express MeCP2. An immunostain or western blot should be 
performed. However, this experiment was not completed in time for this thesis. 
6.6.4 Quantification of glucose uptake 
MT astrocytes showed a slower rate of glucose uptake. Using FACS, I was 
unable to quantify the rate of uptake. A better assay would be to plate equal 
numbers of WT and MT astrocytes into 24 well plates and add 2-NBDG. 
Readings of fluorescent intensity could be taken at various time points such as 
0 min, 10 min, 20 min, 30 min, 60 min using a plate reader. This will provide 
a more accurate quantification of the rate of glucose uptake. 
6.6.5 Identity of the derived cells 
While various specific markers and functional assay was used to determine the 
astrocytic identity of the cells, the data gene expression array could be used to 
further ascertain the identity by checking for cell-type specific genes. This will 
further confirm the lineage of the derived cells. 
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Chapter 7: Investigating the role of microglia in RTT using iPSCs 
7.1 Introduction 
Before 2010, it was generally believed that the cellular culprits in RTT were 
neurons and astrocytes. Then in 2010, a report implicating microglia was 
published (Maezawa and Jin, 2010). In this study, CM from microglia isolated 
from Mecp2-null mice showed neurotoxicity and resulted in WT neurons 
having stunted dendritic development and dendritic beading (Fig 7.1). Further 
investigations found that Mecp2-null microglia released a five-fold higher 
level of glutamate compared to WT microglia and inhibition of both glutamate 
production and glutamate release from Mecp2-null microglia rendered the CM 
less neurotoxic. Inhibition of glutamate receptors in WT neurons also 
decreased the toxic effect of the Mecp2-null microglia, further demonstrating 
that the neurotoxic effect of Mecp2-null microglia was from excessive 
glutamate release. 
 
Fig 7.1 CM from Mecp2-null microglia are neurotoxic. (A) WT neurons 
cultured in WT microglia CM showed normal morphology. (B) and (C) WT 
neurons cultured in CM from Mecp2-null microglia showed signs of 
neurotoxicity such as dendritic beading (arrows) Image reproduced with 
permission from (Maezawa and Jin, 2010). 
 
The role of microglia in RTT was further demonstrated when transplantation 
of WT bone marrow was able to arrest disease progression in Mecp2-null mice 


(Derecki et al., 2012). Repopulation of microglia in the brain from donor 
bone-marrow was shown to be essential for the rescue as prevention of donor 
microglia repopulation in the brain resulted in no arrest of pathology. To 
further verify the role of myeloid cells in RTT, Mecp2lox–stop/yLysmcre mice 
were crossed, resulting in only myeloid cells expressing Mecp2 in an 
otherwise global Mecp2 KO mouse. Mecp2lox–stop/yLysmcre mice showed better 
appearance and growth, and had increased lifespan and reduced respiratory 
symptoms. in vitro investigation of Mecp2-null microglia revealed they have 
reduced phagocytic capacity. Pharmacological treatment of Mecp2lox–
stop/yLysmcre mice with a phagocytosis inhibitor, annexin V blocked 
phagocytotic activity of microglia/macrophage and abolished the amelioration 
of disease showing that phagocytosis activity is needed for rescue of RTT 
symptoms in those mice. 
7.2 Hypotheses and Aims 
The above studies highlighted the role of microglia in the mouse model of 
RTT. It was unclear, however, if microglia would have a role in the human 
RTT. My hypothesis is that human microglia could be a cell type that is 
affected by MeCP2 mutations. To test my hypothesis, I decided to generate 
microglia from a RTT patient’s iPSCs using a novel protocol developed by a 
collaborator. To determine the microglia identity, several microglia markers 
would be used and functional assay would be carried out. 
Due to evidence from the mouse model showing a defect in microglia 
phagocytosis, my hypothesis is that human MT microglia are abnormal in 
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phagocytosis. To investigate this, I aimed to carry out a phagocytosis assay to 
see if MT microglia are abnormal in this aspect. 
Besides abnormal phagocytosis, studies from the mouse model showed that 
Mecp2-null microglia are neurotoxic. My hypothesis is that human MT 
microglia are neurotoxic. To test this hypothesis, I decided to mix the 
microglia with WT human neurons to see if MT microglia have neurotoxic 
effects. The mouse model also demonstrated that the source of neurotoxicity is 
excessive glutamate secretion from Mecp2-null microglia. Hence, I decided to 
test for glutamate secretion to see if this was also true in human MT microglia. 
Furthermore, as MeCP2 is a transcriptional factor, I decided to carry out a 
gene expression study to see if any changes in gene expression between WT 
and MT microglia can be detected.  
7.3 Results 
7.3.1 Derivation of microglia from RTT patient’s isogenic iPSCs 
WT and MT iPSCs from P72 were differentiated to microglia using a novel 
protocol. As microglia originates from the hematopoietic progenitors of the 
yolksac during embryogenesis (Ginhoux et al., 2013), iPSCs were first 
induced into the mesodermal lineage for 5 days before specification to the 
haematopoietic lineage at day 8. Haematopoietic cells were allowed to mature 
for 7 days before addition of factors to expand the cell population. Cells were 
harvested at day 22 (Fig 7.2A). 
To purify the microglia-like cells, live-cell sorting was carried out. CD45, 
CD11b and CD14 are cell surface markers used to identify microglia 
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(Beschorner et al., 2002; Cosenza-Nashat et al., 2006; Wu et al., 2014). The 
cell populations underwent sequentially sorting first using CD45 followed by 
CD11b and then CD14. Both WT and MT iPSCs were able to generate 
microglia at efficiencies of 7-15% based on FACS data (Fig 7.2B&C). To 
further confirm microglia identity, we carried out immunocytochemistry for 
the commonly used microglia markers, Iba1 and CD68 (Ito et al., 1998; 
Kozlowski and Weimer, 2012). All microglia purified by FACS were positive 




Fig 7.2 Derivation and characterisation of iPSCs-derived microglia. (A) 
Schematic of microglia differentiation protocol from iPSCs. Live cell FACS 
using CD-45, CD11B and CD14 of (B) WT iPSCs-derived microglia and (C) 
MT iPSCs-derived microglia. Immunocytochemistry staining of Iba1 and 
CD68 on (D) WT iPSCs-derived and (E) MT iPSCs-derived microglia. Scale 
bar indicates 50µM. Images D & E courtesy of Oz Pomp. 
7.3.2 MT microglia display reduced motility 
Phagocytosis is an innate function of microglia especially in the clearance of 
dead cells and debris. To determine the phagocytic ability of the iPSCs-
derived microglia, we conducted phagocytosis assays. NPCs were irradiated 
under UV lamp in the hood to induce apoptosis and added to microglia culture 
as apoptotic bodies (Derecki et al., 2012). Time lapse microscopy indicates 
both WT and MT microglia have phagocytic ability (Fig 7.3A). However, MT 
microglia was observed to show less phagocytosis of apoptotic bodies (Fig 
7.3B&C).  
 
Fig 7.3 MT microglia showed less phagocytosis of apoptotic bodies. (A) 
Representative images of phagocytosis by iPSCs-derived microglia at 20 
minutes interval. White arrowhead show leading edge of microglia, black 
arrowhead show a labelled apoptotic NPC being phagocytosed (B) 
Representative images of apoptotic body 8 hrs after addition of WT microglia 
and MT microglia. Scale bar represents 100µM. (C) Graphical representation 
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of apototic bodies clearance (mean + SEM, n=3 ** p value<0.01, unpaired t-
test). Images courtesy of Oz Pomp. 
Microglia are highly motile cells and constantly survey their environment with 
frequent filopodia extensions and retractions even while in a resting state 
(Nimmerjahn et al., 2005; Wake et al., 2009). Time lapse microscopy was 
performed on both WT and MT microglia to track their motility over 15 hours. 
MT microglia was observed to display less filopodia process dynamics than 
WT microglia (Fig 7.4A). We further tracked the movement of microglia over 
a 15 hour time period and found that MT microglia were significantly less 
locomotory (Fig 7.4B&C). These findings suggest that motility is impeded in 
MT microglia and reduced motility could be the reason behind a reduced 
phagocytosis. 
 
Fig 7.4 MT microglia showed decreased motility. (A) Photos taken at 10 
minutes intervals showing process dynamics of iPSCs-derived microglia. (B) 
Representative charts showing extent of movement within a 15 hour time 
frame of WT (left) and MT (right) microglia. (C) Graphical representation of 
microglia movement (mean + SEM, ** p-value <0.05, unpaired t-test). Images 





7.3.3 MT microglia are neurotoxic 
It was reported in the mouse model that Mecp2-null microglia are neurotoxic 
(Maezawa and Jin, 2010). To test for neurotoxicity of MT microglia, we set up 
a co-culture system comprising of WT iPSCs-derived neurons and astrocytes 
with the addition of either WT or MT microglia (Fig 7.5A). The unique 
feature of this system is that all cell types are derived from the same patient. 
10 days after co-culture, we observed neuronal beading in co-cultures of 
neurons with MT microglia but not with WT microglia (Fig 7.5A).  
Neuronal beading is an indication of neurotoxicity and it was reported in the 
RTT mouse model that Mecp2-null microglia secreted excessive levels of 
glutamate to cause dendritic beading (Maezawa and Jin, 2010). We therefore 
investigated the levels of glutamate secreted by the iPSCs-derived microglia 
but we did not find significantly increased levels of glutamate secretion by MT 
microglia (Fig 7.5B). We next looked at tumor necrosis factor-α (TNFα) 
secretion levels as it has been reported to induce neurotoxicity by inducing 
glutamate release in microglia (Takeuchi et al., 2006). Both WT and MT 
microglia released TNFα but we did not find elevated levels of TNFα in MT 
iPSCs-derived microglia (Fig 7.5C). These findings suggest that in our iPSC 
model, MT microglia do not secrete excess levels of glutamate or TNFα that 
could be the cause of neuronal beading. Further investigation is necessary to 





Fig 7.5 Co-culture of neurons with MT microglia causes neurotoxicity. (A) 
Schematics showing co-culture setup of multiple cell types with “Control” 
setup comprising of WT neurons, astrocytes and microglia and “Experimental” 
setup comprising of WT neurons and astrocytes with MT microglia. 
Experimental setup resulted in neurons showing beading morphology. Scale 
bar represents 20µM. CM from both WT and MT microglia do not show 
significant differences in (B) glutamate levels or (C) TNFα levels (mean + 
SEM, n=3, *p-value <0.05, ** p-value <0.01, 1-way ANOVA with post-hoc 
Tukey test). Images courtesy of Oz Pomp. 
 
7.3.4 Gene expression study of microglia  
To uncover possible gene targets of MeCP2 in iPSCs-derived microglia, a 
gene expression microarray study comparing WT and MT microglia was 
carried out. 126 differentially expressed genes (DEG) were identified (P-value 
< 0.05; absolute fold change > 1.5) (Appendix 3). Of the 126 genes, 74 were 
up-regulated while 52 were down-regulated in MT microglia. Heat-map 
hierarchical clustering analysis of the 126 genes revealed consistent gene 
expression patterns in WT microglia that were distinct from MT microglia 
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(Fig 7.7) The top 15 up and down regulated genes are shown in Table 7.1 and 
Table 7.2. 
 
Fig 7.6 Heat map cluster analysis of microarray. 121 DEGs were identified 
between WT and MT microglia. 
Table 7.1 Top 15 differentially up regulated genes in MT iPSCs-derived 






Table 7.2 Top 15 differentially down regulated genes in MT iPSCs-
derived microglia based on fold change. 
 
Grouping of the DEG into biological processes which refers to the cellular 
events which the genes contributes revealed enrichment of cholesterol 
metabolism, (i.e metabolism of cholesterol, synthesis of sterol) and motility of 
myeloid cells (i.e chemotaxis of macrophage, cell movement of macrophage) 
(Table 7.3). To look further, pathway analysis of the DEG which looks at the 
metabolic, signaling and regulatory pathways revealed an enrichment of 
pathways involved in cholesterol metabolism (i.e Superpathway of cholesterol 
biosynthesis, cholesterol biosynthesis III) and immune cell functions (antigen 
presentation pathway, granulocyte adhesion and diapedesis) (Table 7.4). 
Taken together, the results suggest that in human microglia, MeCP2 could be a 
regulator of genes involved in cholesterol metabolism, immune cell function 





Table 7.3 Top 15 biological process identified among differentially 
expressed genes based on p-value. 
 
Table 7.4 Top 15 pathway identified among differentially expressed genes 
based on p-value. 
 
To validate the results of the microarray, real-time PCR of selected genes 
including Lysozyme (Lyz); Defensin 1 and 3 (DEFA1 and DEFA3), and 
Ficolin1 (FCN1) was carried out (Fig 7.7). The results showed consistency 




Fig 7.7 Real-time PCR of selected genes. Each graph represents the relative 
fold difference of WT microglia compared to MT microglia (normalized to 1). 
(mean+SEM, **p-value<0.001, unpaired t-test). 
Table 7.5 Comparison of microglia microarray and real-time PCR results 
of selected genes. Values are expressed as MT/WT absolute fold change, with 
positive value denoting up-regulation and negative value denoting down-
regulation in MT microglia. 
 
7.3.5 Comparison of gene expression of different cell types 
Having performed gene expression microarray on NPCs, astrocytes and 
microglia, we wanted to see if there are overlapping genes that are 
differentially expressed across the different cell lines. We compared the list of 
differentially expressed genes in each cell type (Fig 7.8). In summary, 53 
common genes were differentially expressed between NPC and astrocytes, 13 
common genes were differentially expressed between NPC and microglia and 
18 common genes were differentially expressed between astrocytes and 
microglia only. 4 genes were found to be differentially expressed between WT 
and MT cells of all three cell types. The 4 genes are LOC644128, LOC730024, 
Ribosomal Protein L23a Pseudogene 53 (RPL23AP53) and Sex Comb on 
Midleg-Like 1 (SCML1). Moreover, we found that common genes that are 
differentially regulated do not necessarily show the same directional changes. 
For example, of the 13 genes differentially expressed between NPC and 
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microglia, only 8 genes showed the same pattern of expression in terms of up 
or down-regulation. This indicates that MeCP2 regulates the same genes 
differently in different cell types. This could be the reason why whole brain 
microarray between WT and Mecp2-null mouse showed little changes in gene 
expression (Tudor et al., 2002). The list of overlapping genes can be found in 
Appendix 4.  
 
Fig 7.8 Venn diagram show the number of common genes that are 
differentially expressed between WT and MT cells of the different cell 
types. 
7.4 Discussion 
7.4.1 RTT patient’s iPSCs can generate microglia 
The study of microglia has often been dependent on their isolation from rodent 
and human brain but the numbers obtained are typically low (Ford et al., 1995; 
Giulian and Baker, 1986). Immortalized microglia cell lines exist (Bocchini et 
al., 1992) but their properties have been reported to be different from those of 
pimary microglia (Horvath et al., 2008). iPSC-derived microglia represents a 
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useful approach towards acquiring microglia for research and potentially for 
use in regenerative medicine. Here, I described a novel protocol for generating 
microglia from iPSCs. To confirm microglia identity, a panel of microglia 
markers such as CD45, CD11B and CD14 was used to perform live-cell flow 
cytometry. Immunocytochemistry of Iba1 and CD68 further confirmed the 
microglia identity of the purified cells. Motility and phagocytosis assays 
demonstrate that iPSCs-derived microglia display key microglia 
characteristics. These findings demonstrate the usefulness of iPSCs for 
generating microglia for research and potentially, clinical purpose. The added 
advantage we have here is having isogenic WT and MT microglia from the 
same RTT patient (Pomp et al., 2011b). 
7.4.2 MT microglia show motility abnormality 
Microglia are highly motile cells and constantly extend and retract their 
processes (Nimmerjahn et al., 2005). It was reported that microglia from 
Mecp2-null mouse exhibit reduced phagocytosis compared to microglia from 
WT mouse (Derecki et al., 2012). In agreement, our results showed that MT 
microglia had reduced phagocytosis. Time lapse microscopy further revealed 
that MT microglia have less process dynamics and locomotion compared to 
WT microglia. 
How could deficiencies of microglial motility and phagocytosis lead to 
neurological or RTT symptoms? One possibility is that microglia are highly 
motile cells that constantly survey their environment. This surveying activity 
is needed to remodel neuronal network through synaptic pruning and 
phagocytosis of apoptotic cells. Reduction of microglia motility and 


phagocytosis therefore results in deficits in neuronal development. As there is 
a time window for synaptic maturation, this might also be the reason why bone 
marrow transplantation were most effective when carried out early in mice 
(Derecki et al., 2012). Transplantation at a later stage could have missed the 
time window and thus had limited impact. Indeed, a lack of microglia synaptic 
pruning has been found to lead to abnormal brain development in mice 
(Paolicelli et al., 2011; Zhan et al., 2014), and there are evidence that impaired 
microglial phagocytosis might be a cause of neurological symptoms in Nasu-
Hakola disease (Takahashi et al., 2005).  
 
7.4.3 Gene expression study reveals several genes differentially 
regulated in MT microglia 
Our findings suggest MeCP2 could be a regulator of genes involved in 
microglia motility. In support of this theory, our gene expression array 
identified genes and pathways that are involved in cell movement and 
chemotaxis of the myeloid lineage. These genes include DEFA1, CD74 and 
S100A4 all of which are involved in macrophage motility (Frolich et al., 2012; 
Furman et al., 2002; Li et al., 2010b). These genes represent potential genes of 
interest for further investigations. 
In addition to cell movement, our microarray analysis also unexpectedly 
showed an enrichment of pathways involved in cholesterol metabolism as 
being affected in MT microglia. Intriguingly, a recent publication showed that 
modulating cholesterol levels ameliorated some RTT symptoms in the mouse 
model (Buchovecky et al., 2013). In that study, mutation of a gene involved in 
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cholesterol synthesis, squalene epoxidase (Sqle) improved some RTT 
symptoms such as motor dysfunction and longevity. Further investigations by 
the authors uncovered previously unknown abnormal cholesterol levels in 
Mecp2-null mice. Our gene expression screen showed that MT microglia had 
higher expression of genes involved in cholesterol biosynthesis including 
SQLE, CH25H and ACAT2, supporting the evidence that MeCP2 might be a 
regulator of genes involved in cholesterol pathways. It is not known how these 
genes could affect microglia function. One possibility is that abnormal 
cholesterol levels could alter the phagocytic capability and neurotoxicity of 
microglia (Rackova, 2013). Microglia are also known to be a cholesterol 
supply source for young neurons (Funfschilling et al., 2012) and for axon 
growth (Hayashi et al., 2004). Hence any disruption in cholesterol metabolism 
in microglia could affect the development of neurons. Further investigations 
are needed to understand the role of cholesterol metabolism in microglia and 
in RTT. 
7.4.4. MT microglia induce neurotoxicity by an unknown mechanism 
We observed MT microglia induced neurotoxicity when co-cultured with WT 
neurons and astrocytes. We investigated glutamate levels and contrary to the 
mouse system, did not find elevated levels of glutamate secretion from MT 
microglia. We also looked at TNFα, a cytokine secreted by microglia that 
could cause neurotoxicity, but found no differences in secretion levels of MT 
microglia. One possible molecule which we have not looked into at this point 
is Interferon-γ (IFN-γ) which has been reported to cause neuronal beading and 
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is secreted by microglia (Mizuno et al., 2008). The cause of neurotoxicity of 
MeCP2 deficient microglia in human remains to be investigated. 
Based on our findings, we propose a model in which deficiencies in microglia 
function contributes to RTT. In a normal brain, microglia are able to carry out 
its normal function such as debris clearance and contribute to synaptic 
maturation through synaptic pruning (Fig 7.9A). In the RTT brain, microglia 
are unable to carry out its role due to reduced motility and phagocytosis (Fig 
7.9B). Hence, there is an accumulation of debris which can contribute to 
inflammation (Kettenmann et al., 2011; Liu et al., 2006; Majumdar et al., 
2007). Furthermore, microglia are unable to carry out synaptic pruning 
efficiency leading to stunted synaptic maturity (Paolicelli et al., 2011; Zhan et 
al., 2014). 
 
Fig 7.9 Model of how RTT microglia could contribute to RTT. (A) In the 
healthy brain, microglia active performs surveillance to carry out essential 
duties such as debris clearance and synaptic pruning in accordance to the 
neuronal environment. Neurons are healthy and neuronal transmission occurs 
optimally. (B) In the RTT brain, microglia is less active in surveying of 
neuronal environment. In addition, the reduced phagocytosis ability leads to 
less clearance of cellular debris and less synaptic pruning impeding neuronal 


development. RTT microglia may also secrete neurotoxic factor that leads to 
neurotoxicity. All these factors contribute to poor neuronal health and 
exacerbate the RTT phenotype. 
 
7.4.5 The role of microglia in neurological diseases 
Microglia are increasingly being implicated as one of many causes behind the 
pathology of neuro-degenerative diseases such as Alzheimer’s disease and 
Parkinson’s disease (Perry et al., 2010), and also in neuro-psychiatric diseases 
such as depression and schizophrenia (Frick et al., 2013). One example 
however stands out with microglia dysfunction being implicated as the 
primary cause of neuronal symptoms. Nasu-Hakola disease is a disorder in 
which mutations of the Triggering receptor expressed on myeloid cells 2 
(TREM2) gene causes presenile dementia and systemic bone cysts (Bianchin et 
al., 2004; Paloneva et al., 2001). In the CNS, TREM2 is expressed only by the 
microglia and a study showed that impaired phagocytosis and increased 
inflammatory response of microglia could be the cause of neurodegeneration 
in the disease (Takahashi et al., 2005). Much about microglia’s role in 
neurological diseases remains unknown and it is therefore important to 
develop cellular models to gain insight into microglial disease mechanisms. 
Here, we developed a human stem-cell based model to uncover the 
abnormalities of MeCP2 deficient microglia. These work and data provide a 





7.4.6 Different cell types derived from isogenic clones showed different 
changes in gene expression 
From this project, different brain cell types were differentiated from the same 
parental isogenic WT and MT iPSCs lineage. This represents a good 
opportunity to compare gene expression among different cell types. The 
transcriptional profiling done in the different cell types identified several 
genes that are differentially regulated. Comparison of the different gene lists 
showed that different cell types had different changes in gene expression and 
there is no consistent pattern of changes between the cell types (App 4). Of 
the 4 genes that appear in all three cell types, LOC644128 and LOC730024 are 
putative proteins and their function remain unknown. RPL23AP53 stands for 
Ribosomal Protein L23a Pseudogene 53 and is a pseudogene of the Ribosomal 
Protein L23A gene (RPL23A). RPL23A encodes a ribosomal protein that is a 
component of the 60S subunit of ribosomes involved in protein synthesis. 
However, RPL23AP53 has no known function.  SCML1 is an X-linked gene 
and hence differences seen here might be due to differing copy of X-
Chromosome expression. The lack of a clear set common differentially 
expressed genes between the cell types raise the possibility that MeCP2 
regulates genes differently in different cell types. This finding might also 
explain why whole brain gene expression studies between WT and Mecp2-null 
mice showed little changes in gene expression due to a mixture of cells  in the 
brain confounding the results (Tudor et al., 2002). Hence it might be more 
meaningful to compare gene expression of pure populations of cells, rather 




different cell types. Further studies are needed to understand the role of 
MeCP2 amongst different cell types.  
7.5 Conclusions  
In conclusion, I report the successful generation of microglia from RTT iPSCs 
that could recapitulate several microglia characteristics. We found key 
differences between isogenic WT and MT microglia in area of phagocytosis, 
motility and locomotion. MT microglia also have neurotoxic effects not seen 
in WT microglia. Gene expression analysis also uncovered potential targets of 
MeCP2 in microglia. 
7.6 Limitations 
7.6.1 More patients’ samples needed 
Only iPSC lines from P72 were used here. RTT patients differ from one 
another in the range and severity of symptoms. These differences partially 
stem from differing mutations of the MeCP2 gene and different genetic 
backgrounds (i.e. modifier genes). Since the finding in this thesis may 
represent the disease in one patient, it would be beneficial to reproduce these 
experiments in iPSCs lines from additional patients. The strategy was to first 
determine the phenotype to be studied using iPSC lines from one patient 
before extending the findings to other patients. However, the experiments 





7.6.2 Quantification of phagocytosis 
Section 7.3.2 show that MT microglia has reduced phagocytosis in number of 
apoptotic bodies. For a more accurate quantification of phagocytosis rate, 
images of T=0 should be taken to show the number of apoptotic bodies at the 
beginning of the experiment. A larger magnification of the field should be also 
be taken. 
 
7.6.3 Assessment of neurotoxicity 
Due to the low survival rate of neurons when sparsely plated, we could only 
assess neurotoxicity in denser cultures. While we observed neuronal beading 
in the co-culture with MT microglia, we could not quantify the dendritic 
beading frequency in dense cultures. BDNF (a survival factor) could be used 
when plating neurons at low density and withdrawn before conducting the 
assay. Besides neuronal beading, other methods such as measurement of 
dendritic length and quantification of acetylated Tubulin intensity could also 
be used to assess for neurotoxicity (Maezawa and Jin, 2010). 
 
7.6.3 Expression of MeCP2 in iPSC-derived microglia 
While mouse microglia have been shown to express Mecp2 (Maezawa and Jin, 
2010), it is important to show that iPSC-derived microglia express MeCP2. An 
immunostain or western blot should be performed. However, this experiment 
was not completed in time for this thesis. 
7.6.4 Primary cells as positive controls 
While the iPSC-derived microglia show expression of microglia markers and 
demonstrate phagocytosis, a positive control using primary cells is needed for 
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assays such as phagocytosis assay, glutamate release and TNFα release. 
Primary microglia could be isolated from mouse brain as a control (Lee and 




Chapter 8: Conclusions and perspectives 
8.1 Introduction  
The absence of neuronal degeneration in RTT raised hopes that the disease 
may be treatable. Indeed, expression of Mecp2 led to the rescue of RTT 
symptoms in the Mecp2-null mouse (Guy et al., 2007). Follow-up studies 
further identified compounds that improved or rescued specific RTT 
symptoms (e.g. insulin-like growth factor 1 (Tropea et al., 2009), the 
ampakine CX546 (Ogier et al., 2007), fingolimod (Deogracias et al., 2012), 
and statin drugs (Buchovecky et al., 2013). These encouraging findings 
motivated scientists all over the world to further explore the disease. As more 
data accumulated, additional complexities of RTT emerged. For example, the 
traditional belief that RTT is exclusively a neuronal disease was replaced by 
the concept that other brain cell types are also involved and contribute 
significantly to the pathology of the disease (e.g. astrocytes, microglia and 
oligodendrocytes (Ballas et al., 2009; Maezawa and Jin, 2010; Maezawa et al., 
2009; Nguyen et al., 2013). This knowledge in turn led to novel potential 
therapeutic strategies including bone marrow transplantation as a means of 
supplementing the brain with WT monocyte that could play the role of 
microglia (Derecki et al., 2012). The focus of my thesis was to investigate the 
impact of MeCP2 mutations on less explored features of brain development 
such as neural progenitor migration as well as contributions from other 
neuronal and non-neuronal cell types like astrocytes and microglia 
respectively. Through reprogramming of female patient fibroblasts, I was able 
to prepare isogenic iPSC lines, which either expressed WT or MT MeCP2. 
Using the isogenic lines from a patient with a 1155del32bp mutation in 
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MeCP2, I identified novel phenotypes in resident brain cells, some of which 
have never been implicated in the disease before (e.g. NPCs).  
8.2 The use of iPSCs to model RTT  
“If our brains were simple enough for us to understand them, we'd be so 
simple that we couldn't” - Ian Stewart (professor, writer). The lack of 
understanding of our own brains makes it particularly challenging for us to 
understand diseases which result from complex interactions between different 
brain cells. Thus, although it is an over-simplification, disease modeling in a 
dish is a good strategy to isolate and address questions regarding to brain 
diseases. In this thesis I demonstrated the generation of pure populations of 
different types of RTT afflicted cells. Importantly, for each cell type, I 
generated both experimental MT cells, and as a perfect control, WT cells from 
the same patient. This allowed me to get new insights regarding the effects of 
loss of function of MeCP2 on a specific cell type (e.g. reduced motility in 
mutant microglia, deficient in proliferation potential in astrocytes) and also to 
predict potential phenotypes in vivo (see next section). Examining MeCP2 
transcriptional regulation in specific cell types is a classic example of one of 
the advantages of iPSCs technology. While microarray analysis for brain 
samples which are composed of different cell types may produce confounding 
information, comparison of homogeneous and isogenic populations of iPSCs 
derived cells produced informative results.  
8.3 Predictions in the patient based on in vitro observations 
In vitro models are vastly simplified. They give an indication of the phenotype 
but may not be relevant to the in vivo condition.  Based on my results in this 
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work, I will attempt to link how these observations can affect the RTT patient. 
For example, mutations in MeCP2 can cause migration deficiencies in NPCs, 
and that the presence of WT NPCs partially alleviates this phenotype. Thus, 
this data may explain a later onset of the disease in females compared to an 
early onset of the disease in male.  However, there is so far no evidence that 
NPCs are affected in RTT patients. 
The finding of increased PDGF secretion by MT astrocytes and results from 
gene expression microarray suggest that MT astrocytes may cause leakiness of 
the BBB. This could be relevant to RTT patients as disruption of BBB is 
thought to be a major cause of epilepsy (Marchi et al., 2011; Oby and Janigro, 
2006), and may be a cause of seizures in RTT patients. However, there is so 
far no evidence showing that BBB is affected in RTT patients. 
In addition, I found that MT microglia are less motile and have less 
phagocytosis in vitro. If this is the situation in the RTT brain, there could be 
insufficient debris clearance and synaptic pruning which have the potential to 
contribute to symptoms as seen in the mouse model (Derecki et al., 2012). I 
also observed MT microglia are neurotoxic. This can lead to damages of 
neuronal axons and dendrites (Maezawa and Jin, 2010) (Takeuchi et al., 2005). 
Preliminary studies of microglia dysfunction have been shown in mice in vivo 
model (Derecki et al., 2012), but have not been shown in RTT patients.  
Figure 8.1 illustrates some of the findings and predictions based on this work. 
Astrocytes through increased PDGF-AA secretion (Fig 8.1A) can cause 
leakiness of the BBB (Fig 8.1B). Astocytes also increase activation of 
microglia due to reduced secretion of fractalkine (Fig 8.1C). Microglia are 


deficient in phagocytosis (Fig 8.1D) which could cause accumulation of debris 
(Fig 8.1E) which in turn leads to poor neuronal health. 
 
Fig 8.1 Proposed model for how astrocytes and microglia can contribute 
to the RTT pathology based on findings. MT neurons are dysfunctional in 
terms of neurotransmission due to reduced synapse numbers and dendritic 
arbors. This is further exacerbated by several deficiency in glia functions. (A) 
Over-secretion of PDGF from MT astrocytes could lead to leaky BBB thus 
enabling (B) infiltration of plasma proteins and immune cells from the 
peripheral circulation. This leads to the imbalance of the CNS environment 
homeostasis. (C) MT astrocyte releases less fractalkine which increases 
activation of microglia. (D) Reduced phagocytosis by MT microglia leads to 
(E) buildup of debris and causes reduced neuronal health. Note that the RTT 
brain contains a mixture of WT and MT cells but only MT cells are depicted 





8.4 Future directions 
8.4.1 The role of RTT astrocytes in BBB maintenance 
The BBB is a specialised structure comprising of three main cell types- the 
endothelial cells lining the brain vasculature, the astrocytes whose endfeet 
surround the blood vessel, and the pericytes which are embedded between the 
endothelial cells and astrocytes. One important function of the BBB is to 
control the transport of substances between the blood and brain. The tight 
junctions that forms between the endothelial cells are essential in regulating 
the transport of many molecules and ions. In addition to the cellular 
component, ECM proteins in the basement membrane between the endothelial 
cells and astrocytes are involved in BBB functions. 
 
Astrocytes play an important role in inducing endothelial cells to form tight 
junctions (Janzer and Raff, 1987; Kuchler-Bopp et al., 1999). As microarray 
results revealed that blood vessel function and cell adhesion as pathways that 
are affected in MT astrocytes, I propose that MT astrocytes could cause BBB 
leakiness due to a reduction of cell to cell contact between astrocytes-astrocyte 
and astrocytes with the other cell types such as endothelial cells and pericytes. 
The transwell assay is an in vitro method used to assay the permeability of the 
BBB (Fig 8.2A) (Lippmann et al., 2014; Urich et al., 2013; Wong et al., 2013). 
In this assay, a confluent layer of endothelial cells is plated onto a porous 
membrane that separates two chambers. Astrocytes and pericytes can be 
seeded onto the opposite side of the membrane or in the bottom of the 
chamber. A dye or ions can be introduced into the apical side of the insert and 
the medium on the basolateral side can then be spectroscopically measured for 
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leakiness of the dye or a conductivity probe can be used to detect changes in 
conductivity. 
  
Another way which MT astrocytes could affect BBB leakiness is through 
excessive PDGF-AA. Though the mechanism is unknown, it is possible that 
pericytes play an important role in mediating PDGF effects as pericytes are 
known to express PDGF receptors (Arimura et al., 2012; Quaegebeur et al., 
2010; Winkler et al., 2010). The transwell assay could also be used to test for 
the effects of PDGF-AA on BBB leakiness by addition of varying levels of 
PDGF-AA or PDGFR inhibitors. Investigation of BBB integrity can also be 
done in a Mecp2-null mouse model by injecting a dye which binds to plasma 
protein (i.e Evans Blue), and checking for infiltration of the dye in the brain 
using optical imaging (Fig 8.2B) (Jaffer et al., 2013). 
 
 
Fig 8.2 Assays for measuring BBB permeability. (A)  The transwell in vitro 
assay consists of endothelial cell plated on the apical side of a microporous 
membrane and pericytes/astrocytes plated on the basolateral side. Fluorescent 
probes or ions can be introduced to the apical side and the movement of the 
probe or ions can be determined on the basolateral side. (B) In vivo assay is 
performed by injecting a probe into the blood of an animal model. Imaging 
technique can then be used to detect presence of the probe in the brain of the 




8.4.2 Testing of the lactate shuttle hypothesis 
Preliminary evidence from this project suggests that the astrocytes have deficit 
in taking up glucose. If this is the case, it is possible that astrocytes are unable 
to provide enough metabolites in times of high neuronal demand. According to 
the astrocyte-neuron lactate shuttle hypothesis, glucose is taken up by 
astrocytes and converted to lactate to be used as an energy source for neurons 
(Escartin et al., 2006; Figley, 2011; Pellerin et al., 1998). When the lactate 
shuttle is affected in mice, cognitive functions and working memory were 
found to be impaired (Newman et al., 2011; Suzuki et al., 2011) . To further 
find out the effects of delayed glucose consumption in MT astrocytes, lactate 
production of iPSC-derived astrocytes can be measured to see if it is affected. 
The astrocytes could also be stimulated by electrical stimulation or glutamate 
to see if glucose uptake and lactate production is affected. Another important 
component is to check glycogen levels as astrocytes are known to have a 
glycogen storage and convert it into lactate for release in times of neuronal 
activity (Brown and Ransom, 2014; Brown et al., 2005; Tarczyluk et al., 2013). 
Together, this series of studies will provide a better idea of how astrocytic 
metabolics are affected in RTT. 
8.4.3 Microglia transplantation as a therapeutic for RTT 
In the mouse study, WT bone marrow transplant ameliorated RTT symptoms 
in mice. This raised the possibility that bone marrow transplant could be used 
as a treatment for RTT. However, donor bone marrows are in short supply and 
the chance of finding a bone marrow match is slim. As a validation of the 




mouse model to test if RTT symptoms can be ameliorated. As microglia are 
highly motile cells, they are able to migrate from the site of transplantation as 
demonstrated in microglia transplantation studies carried out in mouse models 
of Alzheimer’s disease and cerebral ischemia (Narantuya et al., 2010; Takata 
et al., 2007). This makes microglia a more suitable cell type for transplantation 
in RTT than other neural cell types. This will be a proof of concept study and 
could lead to development of a potential therapeutic strategy for RTT. 
8.4.4 Investigation of MeCP2 target genes  
The microarray analyses revealed several genes that might be targets of 
MeCP2 for each cell type. More in-depth study should be done to study these 
pathways. For example, the cholesterol pathway was highly enriched in the 
pathway analysis between WT and MT microglia.  Further work should be 
done to determine how cholesterol synthesis is affected in microglia, and how 
disruption of this process could lead to neurological symptoms. Next, if it is 
determined that cholesterol synthesis is affect, cholesterol level modulating 
drugs could be used to see if any MT microglia phenotype could be rescued. 
8.4.5 Development of a stem-cell based high-throughput assay  
The lack of a cell based system for high-throughput compound screening has 
been a challenge for neurological disorders (Jain and Heutink, 2010). Stem 
cells offer an unlimited source of material for drug-screening due to their 
unlimited proliferation and potential for differentiation. An excellent example 
of a stem cell based model was presented by Scholer et al., 2012. In this study, 
the authors co-cultured astrocytes, motor neurons and microglia to screen 10 
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000 small molecule compounds that can inhibit microglia-mediated toxicity 
(Fig 8.3). The study was done mainly with rodent ESC derivatives, but in this 
thesis, I have demonstrated that it is possible to get the cellular derivatives 
from human iPSCs and this could be a more clinically relevant model when 
doing drug screening. 
 
Fig 8.3 High-throughput compound screening using stem cells derivatives. 
A co-culture system consisting of microglia, motor neurons and astrocytes 
from mouse. Image reproduced with permission from (Hoing et al., 2012) 
 
8.5 Concluding remarks 
Much has been uncovered since the identification of MeCP2 as the main cause 
of RTT. While in vitro disease modeling at present is limited in its ability to 
reveal the complex interactions between different cells in the brain, it provides 
a simplified system to identify cell specific phenotypes and to reveal 
molecular and biochemical pathways.  This technology is just making its first 
‘proof of principle’ infant steps. I set out on this project to better understand 
how RTT happens. By submitting this work I feel privileged to add a step to 
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Appendix 1: List of DEGs in NPCs 
Symbol Absolute fold 










































































































































































































































































































































































































































































































































































































Appendix 2: List of DEGs in 
astrocytes 
Symbol Absolute fold 


















































































































































































































































































































































































































































































































































































































Appendix 3 : List of DEGs in 
Microglia  
Symbol Absolute fold 









































































































































































AK3L1 2.431236 -2.19142 
BIRC3 -2.030648 2.209313 
CYP26B1 -2.134999 4.096772 
DKK3 2.432633 2.260261 
EGFL6 2.46241 -4.08214 
FLJ30428 2.012406 83.58686 
LOC644128 3.65873 5.046595 
LOC645166 2.398337 2.521895 
LOC730024 2.00854 6.500651 
LYZ -2.353674 -2.01732 
RPL23AP53 9.220812 5.13234 
SCML1 -3.396236 -2.43032 





ACAT2 2.5227 -2.0615 
CCND1 2.2598 -2.1637 
CSRP1 -2.6777 -68.9403 
CXCR7 2.8157 3.1050 
FLJ41603 2.7963 -2.7822 
HP -2.169 -31.4574 
KCNQ2 -2.2796 3.1506 
LOC440160 2.5123 3.7355 
LOC644128 3.6587 33.4058 
LOC730024 2.0085 4.5114 
NEFM -2.5579 4.7235 
NMU -3.0915 -2.4147 
RPL23AP53 9.2208 29.1358 
SCML1 -3.3962 -4.7735 
SIK1 2.0472 -2.5941 
SLC15A4 5.6956 2.2572 
TAF7 -2.0714 -2.0825 







ADM 2.838582 2.0452 
BCL11A -2.4249 2.5631 
C13orf15 2.2759 2.1155 
C1orf61 -4.2115 31.9446 
C20orf103 -2.4718 2.6620 
C20orf72 2.2019 2.2232 
CABP7 -2.8820 3.3890 
CXCL12 -4.3615 -6.5519 
DBC1 -2.1639 -7.6715 
DPPA4 3.9325 5.6255 
ELMOD1 2.0456 -2.7685 
FABP7 -3.4073 2.9876 
FZD6 -2.6213 5.6895 
GABBR2 -5.2874 3.1883 
HS3ST1 -2.4709 -3.8269 
IFITM1 -2.4346 -2.2386 
INHBB -2.2568 -2.8302 
IRX2 165.8720 162.4895 
KLHL4 2.0540 -2.5897 
LAMA4 -2.0540 -2.3044 




LOC295943   
LOC285943 -3.0187  
LOC387763 -2.3437 2.5147 
LOC644128 5.0466 33.4058 
LOC644632 2.1569 3.6047 
LOC647322 2.1569 99.0702 
LOC650909 -2.1569 -2.6404 
LOC653458 2.4269 3.7034 
LOC654433 49.0226 25.8659 
MAB21L2 -2.1165 -3.2936 
MGC16121 2.3256 2.5333 
MIAT 2.3975 2.2864 
MKRN3 2.0909 2.2047 
MOXD1 -2.0355 4.1727 
NTRK2 -2.0305 2.5504 
OGDHL -2.2262 -6.0235 
OLFM1 -2.3394 -4.1184 
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PCDHB5 -86.9776 -143.5786 
PEG3 -957.219 -33.9225 
PGM5 -4.2148 9.0949 
PPARGC1A -2.2928 -4.7715 
PTX3 2.6689 2.0547 
RGPD1 -2.8554 -12.1798 
SPOCK1 6.3553 -2.1866 
TCEAL2 -4.8414 2.7982 
TMEM132D 118.4605 311.2420 
TMEM200A -2.8407 -5.9045 
VCAM1 -2.0800 7.3126 
VGLL3 5.5148 2.4002 
XIST 2.0657 3.4956 
 
